EP0948612A2 - Beta-amyloid toxicity - Google Patents
Beta-amyloid toxicityInfo
- Publication number
- EP0948612A2 EP0948612A2 EP97952623A EP97952623A EP0948612A2 EP 0948612 A2 EP0948612 A2 EP 0948612A2 EP 97952623 A EP97952623 A EP 97952623A EP 97952623 A EP97952623 A EP 97952623A EP 0948612 A2 EP0948612 A2 EP 0948612A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- animal
- gene
- transgenic
- transgene
- transparent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000006974 Aβ toxicity Effects 0.000 title description 2
- 230000009261 transgenic effect Effects 0.000 claims abstract description 107
- 108700019146 Transgenes Proteins 0.000 claims abstract description 79
- 238000000034 method Methods 0.000 claims abstract description 74
- 231100000331 toxic Toxicity 0.000 claims abstract description 50
- 230000002588 toxic effect Effects 0.000 claims abstract description 50
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 14
- 241000244203 Caenorhabditis elegans Species 0.000 claims abstract description 10
- 238000001727 in vivo Methods 0.000 claims abstract description 9
- 241001465754 Metazoa Species 0.000 claims description 161
- 108090000623 proteins and genes Proteins 0.000 claims description 149
- 150000001875 compounds Chemical class 0.000 claims description 67
- 230000014509 gene expression Effects 0.000 claims description 58
- 102000004169 proteins and genes Human genes 0.000 claims description 47
- 108700008625 Reporter Genes Proteins 0.000 claims description 31
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 28
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 28
- 239000005090 green fluorescent protein Substances 0.000 claims description 28
- 239000003550 marker Substances 0.000 claims description 24
- 238000012360 testing method Methods 0.000 claims description 19
- 231100000419 toxicity Toxicity 0.000 claims description 18
- 230000001988 toxicity Effects 0.000 claims description 18
- 230000001225 therapeutic effect Effects 0.000 claims description 12
- 230000001939 inductive effect Effects 0.000 claims description 11
- 241000244206 Nematoda Species 0.000 claims description 10
- 230000003915 cell function Effects 0.000 claims description 5
- 230000013011 mating Effects 0.000 claims description 5
- 230000009467 reduction Effects 0.000 claims description 2
- 230000035939 shock Effects 0.000 claims 1
- 238000012800 visualization Methods 0.000 abstract description 3
- 230000007082 Aβ accumulation Effects 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 44
- 210000004027 cell Anatomy 0.000 description 36
- 208000024827 Alzheimer disease Diseases 0.000 description 32
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 26
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 23
- 201000010099 disease Diseases 0.000 description 23
- 230000000694 effects Effects 0.000 description 23
- 150000001413 amino acids Chemical class 0.000 description 19
- 239000003814 drug Substances 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 18
- 229940079593 drug Drugs 0.000 description 16
- 239000012634 fragment Substances 0.000 description 14
- 150000007523 nucleic acids Chemical group 0.000 description 14
- 239000013598 vector Substances 0.000 description 14
- 210000002569 neuron Anatomy 0.000 description 13
- 238000003752 polymerase chain reaction Methods 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 108010035532 Collagen Proteins 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 101100528916 Caenorhabditis elegans rol-6 gene Proteins 0.000 description 11
- 108091026890 Coding region Proteins 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 11
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 206010012289 Dementia Diseases 0.000 description 10
- 238000011161 development Methods 0.000 description 10
- 230000018109 developmental process Effects 0.000 description 10
- 238000012216 screening Methods 0.000 description 10
- 208000037259 Amyloid Plaque Diseases 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 210000003205 muscle Anatomy 0.000 description 9
- 239000013615 primer Substances 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 230000006399 behavior Effects 0.000 description 8
- 210000000663 muscle cell Anatomy 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000005096 rolling process Methods 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- 230000004927 fusion Effects 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 230000009977 dual effect Effects 0.000 description 6
- 241000251468 Actinopterygii Species 0.000 description 5
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 5
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 5
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000004602 germ cell Anatomy 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 210000000287 oocyte Anatomy 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 241000252212 Danio rerio Species 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 101150056134 lacL gene Proteins 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 101100347613 Caenorhabditis elegans unc-54 gene Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000023105 Huntington disease Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108010071690 Prealbumin Proteins 0.000 description 3
- 102000009190 Transthyretin Human genes 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 210000003050 axon Anatomy 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 210000001787 dendrite Anatomy 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000005014 ectopic expression Effects 0.000 description 3
- 210000002149 gonad Anatomy 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 230000001418 larval effect Effects 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 3
- 229960001685 tacrine Drugs 0.000 description 3
- 238000002834 transmittance Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 201000010374 Down Syndrome Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- 102000029797 Prion Human genes 0.000 description 2
- 208000024777 Prion disease Diseases 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 206010044688 Trisomy 21 Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 108091005971 Wild-type GFP Proteins 0.000 description 2
- 241000269370 Xenopus <genus> Species 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001147 anti-toxic effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 210000004720 cerebrum Anatomy 0.000 description 2
- PBKVEOSEPXMKDN-LZHUFOCISA-N chembl2311030 Chemical class CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)CC)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 PBKVEOSEPXMKDN-LZHUFOCISA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 210000002932 cholinergic neuron Anatomy 0.000 description 2
- -1 cofactors Substances 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 210000001652 frontal lobe Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 210000001044 sensory neuron Anatomy 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000242764 Aequorea victoria Species 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 108010060159 Apolipoprotein E4 Proteins 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 102100035029 Ataxin-1 Human genes 0.000 description 1
- 108010032963 Ataxin-1 Proteins 0.000 description 1
- 102000007370 Ataxin2 Human genes 0.000 description 1
- 108010032951 Ataxin2 Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000244202 Caenorhabditis Species 0.000 description 1
- 101100292356 Caenorhabditis elegans mtl-2 gene Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000015833 Cystatin Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010014935 Enzyme abnormality Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 102000004878 Gelsolin Human genes 0.000 description 1
- 108090001064 Gelsolin Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 description 1
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
- 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 102000008763 Neurofilament Proteins Human genes 0.000 description 1
- 108010088373 Neurofilament Proteins Proteins 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- XFFSCOOTVXBLCK-QAVVBOBSSA-N OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)-c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O Chemical compound OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)-c1ccc(cc1)\N=N\c1ccc(O)c(c1)C(O)=O XFFSCOOTVXBLCK-QAVVBOBSSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
- 102000015499 Presenilins Human genes 0.000 description 1
- 108010050254 Presenilins Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 241000242583 Scyphozoa Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 1
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 210000003323 beak Anatomy 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 150000001607 bioavailable molecules Chemical class 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000001052 bipolar neuron Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 239000003541 chymotrypsin inhibitor Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 208000030251 communication disease Diseases 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 108050004038 cystatin Proteins 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940040520 ergoloid mesylates Drugs 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 208000019995 familial amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 102000055647 human CSF2RB Human genes 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 101150079143 mec-4 gene Proteins 0.000 description 1
- 210000001767 medulla oblongata Anatomy 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000004879 molecular function Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000003078 multipolar neuron Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 210000000869 occipital lobe Anatomy 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 210000001152 parietal lobe Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229960001697 physostigmine Drugs 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical group C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 108010040003 polyglutamine Proteins 0.000 description 1
- 229920000155 polyglutamine Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000007261 regionalization Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 101150080312 rol-6 gene Proteins 0.000 description 1
- 102200076454 rs104894848 Human genes 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000016978 synaptic transmission, cholinergic Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011820 transgenic animal model Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 201000007905 transthyretin amyloidosis Diseases 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000003242 unipolar neuron Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
- A01K67/0333—Genetically modified invertebrates, e.g. transgenic, polyploid
- A01K67/0335—Genetically modified worms
- A01K67/0336—Genetically modified Nematodes, e.g. Caenorhabditis elegans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/20—Animal model comprising regulated expression system
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/70—Invertebrates
- A01K2227/703—Worms, e.g. Caenorhabdities elegans
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0337—Animal models for infectious diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0393—Animal model comprising a reporter system for screening tests
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Definitions
- the present invention is in the field of medicine and molecular biology.
- the invention provides transgenic non-human animals in which expression of a reporter gene is induced by a toxic transgene.
- the invention also provides methods and compositions for in vivo visualization of the toxicity associated with toxic proteins.
- the present invention provides methods and compositions for the production and use of transgenic non-human animals for screening candidate drugs to assess and treat toxicity.
- Alzheimer's disease is associated with the majority of dementia cases in the United States, with an estimated 2 million people afflicted with the disease, and a mortality rate of approximately 100,000 people per year (See, R.W.P. Cutler, "Degenerative and Hereditary
- Alzheimer's disease Patients suffering from Alzheimer's disease typically suffer progressive memory deficit, progressive decline in cognitive functions, anxiety, depression, visuospatial and speech deficits, delusions, personality changes, motor skill deterioration, loss of verbal ability, and incontinence. Eventually, patients are completely incapacitated and disoriented, requiring total care. The course of Alzheimer's disease ranges from less than three years to over 20 years before death occurs. However, in typical cases, it progresses at a fairly constant rate, with an average duration of 6 to 10 years. Alzheimer's disease is not the only cause of dementia. Indeed, there are over fifty recognized causes of dementia. As some causes of dementia are amenable to treatment, differential diagnosis of patients suffering dementia is particularly important. Because at least 20% of clinically diagnosed patients were found at autopsy to have had conditions other than Alzheimer's disease, the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and Alzheimer's Disease and Related Disorders
- NINCDS National Institute of Neurological and Communicative Disorders and Stroke
- Alzheimer's disease was refined the clinical diagnostic criteria for Alzheimer's disease (See, M.A. Jenike, "Psychiatry,” in Medicine, Scientific American, New York, [1991], pages 13 (V):l-5). Based on these criteria, the diagnosis of Alzheimer's disease may be "definite” (i.e., requiring examination of brain tissue), "probable” (i.e., patients have deficits in two or more areas of cognition, insidious onset of disease, progressive worsening of memory and other cognitive functions, and normal consciousness levels), or "possible” (i.e., patents meet the criteria for probable Alzheimer's disease, but exhibit variations in the disease course or have a systemic illness that is sufficient to cause dementia, but is not considered to be the cause of the dementia).
- definite i.e., requiring examination of brain tissue
- probable i.e., patients have deficits in two or more areas of cognition, insidious onset of disease, progressive worsening of memory and other cognitive functions, and normal consciousness levels
- the histopathological lesions of Alzheimer's disease include neuritic or senile plaques, neurofibrillary degeneration, and granulovacuolar neuronal degeneration.
- the senile plaques usually contain a core of insoluble, amyloidic extracellular material (" ⁇ - amyloid) surrounded by a halo of neurofibrillary tangles and dystrophic neurons.
- amyloidic core of senile plaques The primary protein component of the amyloidic core of senile plaques is a 4.2 kd amyloid ⁇ peptide (often referred to as "A ⁇ ").
- a number of other proteins have also been identified as components of senile plaques, including anti-chymotrypsin and apolipoprotein E.
- the major component of the neurofibrillary tangles is an abnormally phosphorylated microtubule-associated protein referred to as "tau.”
- the ⁇ -amyloid protein in senile plaques is a small glycoprotein (i.e., a 39-43 amino acid protein, derived from the larger amyloid precursor protein), that has been detected in non-neural tissues (e.g., skin, subcutaneous tissue, and intestines) and blood vessels of Alzheimer's disease patients (See, Cutler, supra). Deposits of amyloid may be detected by their ability to bind specific dyes, such as Congo red or thioflavin S. Thus, it has been further hypothesized that detection of this protein may serve as a potential diagnostic aid in the assessment of patients suffering from dementia.
- Alzheimer's disease usually arises spontaneously, although genetics play a role in development of the disease.
- the histopathologic lesions of Alzheimer's disease have been regularly observed in the brains of older patients dying of Down's syndrome (See, Cutler, supra).
- the ⁇ -amyloid gene resides on chromosome 21.
- As Down's patients have an extra copy of this chromosome there is an increased expression of this chromosome in these patients.
- increased expression of the ⁇ -amyloid gene may regulate the formation of amyloid plaques ("senile plaques") in these patients.
- four loci were recently identified as playing a role in the genetic susceptibility of Alzheimer's disease (See, Pericak-Vance and Haines (1995) Trends Genet. 11:504).
- Alzheimer's disease Other potential risk factors for the development of Alzheimer's disease include environmental factors (e.g., head trauma, smoking, and exposure to heavy metals), sociological factors (e.g., depression and educational level), biological factors (e.g., increasing age and hyperthyroidism), and a family history of Alzheimer's disease, Down's syndrome, or Parkinson's disease (See, Pericak-Vance and Haines, supra). Nonetheless, despite recent advances, the exact etiology and pathogenesis of Alzheimer's disease remain largely unknown.
- environmental factors e.g., head trauma, smoking, and exposure to heavy metals
- sociological factors e.g., depression and educational level
- biological factors e.g., increasing age and hyperthyroidism
- a family history of Alzheimer's disease e.g., Down's syndrome, or Parkinson's disease (See, Pericak-Vance and Haines, supra). Nonetheless, despite recent advances, the exact etiology and pathogenesis of Alzheimer's disease remain
- cholinergic enhancers e.g., choline and lecithin
- cholinergic precursors have been shown to be not useful, although some drugs that stimulate cholinergic transmission may be helpful in some patients.
- physostigmine a compound that prevents the synaptic breakdown of acetylcholine.
- the overall clinical effect of this drug has not been as dramatic as initially hoped
- THA tetrahydroaminoacridine
- tacrine a centrally acting anti-cholinesterase
- Reporter genes are genes that encode proteins or other compounds that can be detected by a variety of methods, and which "report" the occurrence of successful introduction and expression of gene sequences, ⁇ -galactosidase and luciferase are examples of such reporter genes.
- GFP green fluorescent protein
- U.S. Patent No. 5,491 ,084 This gene can provide a method for indicating expression of a gene via fluorescent detection of GFP.
- the drawback to using GFP in mammalian systems is as described above, that is, the need to sacrifice the mammal in order to analyze the cells and tissues of interest. This drawback is especially severe in the context of large-scale screening of potential therapeutic compounds, and U.S. Patent No. 5,491,084 does not describe a system suitable for high- throughput screening of pharmaceuticals for activity against toxic proteins expressed in cells.
- the present invention provides methods and compositions useful for the production and use of dually transgenic animals, in particular Caenorhabditis elegans.
- the present invention provides transparent animals that express a reporter gene inducible by a toxic transgene.
- the toxic transgene encodes ⁇ -peptide.
- the reporter gene is green fluorescence protein (GFP). It is contemplated that the effects or product of the reporter gene be observable (i.e., the reporter gene is expressed). For example, in embodiments in which GFP is the reporter, its presence is detected using fluorescence microscopy.
- the animals do not need to be sacrificed in order to observe the expression of the reporter gene (i.e., the detection may be accomplished on living animals).
- lacZ expression may be detected by exposing the tissues of the animal to the substrate for the gene (i.e., ⁇ -galactoside), and observing for the presence of blue dye in the tissues.
- the substrate for the gene i.e., ⁇ -galactoside
- this method requires that the animal be sacrificed in order to observe the expression of the reporter gene.
- the genome of the transparent animal further contains a heterologous marker gene.
- the marker gene is rol-6(su- 1006).
- expression of the marker gene is accomplished by observing the living animals for the rolling behavior that results due to the expression of the abnormal collagen gene. In contrast, wild-type animals exhibit normal locomotion and do not exhibit this rolling behavior, as their collagen is normal.
- the first transgene of the dually transgenic non- human animal comprises pCL25.
- the second transgene of the dually transgenic non-human animal comprises pCL12.
- the genome of the transparent animal further contains a heterologous marker gene.
- the marker gene is rol-6(su-1006).
- expression of the marker gene is accomplished by observing the living animals for the rolling behavior that results due to the expression of the abnormal collagen gene. In contrast, wild-type animals exhibit normal locomotion and do not exhibit this rolling behavior, as their collagen is normal.
- the transparent animal is selected from the class Nematoda. Although it is not intended that the transparent animal of the present invention be limited to any specific animal, in a particularly preferred embodiment, the transparent animal is Caenorhabditis elegans. In an alternate embodiment the cells of the transparent animal display toxicity resulting from the accumulation of ⁇ -peptide within the cells. In one preferred embodiment, the genome of the transparent animal comprises SEQ ID NO: 5 and SEQ ID NO:8.
- the present invention also provides methods for producing dually transgenic non- human animal comprising: providing: a first and second non-human animal; a first transgene comprising ⁇ -peptide; and a second transgene, comprising a reporter; introducing the first transgene into the genome of the first non-human animal to produce a first transgenic animal, and introducing the second transgene into the genome of the second non-human animal to produce a second transgenic animal; and mating the first transgenic animal with the second transgenic animal to produce a dually transgenic animal, wherein the ⁇ -peptide and the reporter are expressed.
- the dually transgenic non-human animal is transparent.
- the transparent animal is a nematode, while in a particularly preferred embodiment, the animal is Caenorhabditis elegans.
- the first transgene of the dually transgenic non- human animal comprises pCL25.
- the second transgene of the dually transgenic non-human animal comprises pCL12.
- the genome of the transparent animal further contains a heterologous marker gene.
- the marker gene is rol-6(su-1006).
- expression of the marker gene is accomplished by observing the living animals for the rolling behavior that results due to the expression of the abnormal collagen gene. In contrast, wild-type animals exhibit normal locomotion and do not exhibit this rolling behavior, as their collagen is normal.
- the present invention also comprises methods for testing compounds for anti-toxic effects, comprising: providing a dually transgenic non-human animal expressing a toxic transgene and a reporter; a composition comprising a test compound in a form suitable for administration such that the compound is bioavailable in the cells of the animal; and administering the test compound to the non-human animal.
- the toxic transgene induces expression of the reporter gene.
- the toxic transgene is ⁇ - peptide and the reporter gene is GFP.
- the method further comprises the step of measuring a reduction or increase in the expression of the reporter by the dually transgenic non-human animal and thereby identifying a compound as therapeutic.
- the compounds inactivate the ⁇ -peptide expressed by the dually transgenic animal.
- the dually transgenic non-human animal is transparent.
- the transparent animal is a nematode, while in a particularly preferred embodiment, the animal is Caenorhabditis elegans.
- the first transgene of the dually transgenic non-human animal comprises pCL25.
- the second transgene of the dually transgenic non-human animal comprises pCL12.
- the genome of the transparent animal further contains a heterologous marker gene.
- the marker gene is rol-6(su-1006), which produces effects described herein.
- test compounds are tested for their ability to counter the toxic effects of transgene product. It is also contemplated that the test compounds will be tested for their ability to prevent the expression of the toxic transgene, for example, ⁇ -peptide.
- dually transgenic animals in which the expression of, or effects of transgene toxicity, are reduced or eliminated by the test compounds are mated. The progeny of these matings are also then tested for the effects of test compounds on the expression of, or effects of toxicity. In yet another embodiment, the progeny of these matings are used in other assay systems for the identification of therapeutic compounds.
- the dually transgenic animals of the present invention are used to identify methods suitable for the diagnostic testing of Alzheimer's disease or pathology due to other diseases.
- the dually transgenic animals of the present invention are used to develop assays suitable for use in humans or animal models of Alzheimer's disease.
- DESCRIPTION OF THE FIGURES Figure 1 is a diagram illustrating the construction of dual transgenic animals expressing ⁇ -amyloid peptide and an hsp/GFP reporter.
- Figure 2 shows the DNA sequence (SEQ ID NO:5) and restriction map for pCL12.
- Figure 3 is a graphic map of pCL12.
- Figure 4 shows the DNA (SEQ ID NO:6), and amino acid sequence (SEQ ID NO:7) of pCL12 from nucleotide 1071 through 1253 (i.e., the ⁇ -(l-42) nucleic acid and amino acid sequence).
- Figure 5 shows the DNA sequence (SEQ ID NO: 8) and restriction map for pGFP-
- Figure 6 is a graphic map of pGFP-TT.
- Figure 7 shows the DNA sequence (SEQ ID NO:9) and restriction map for pCL25.
- Figure 8 is a graphic map of pCL25.
- Figure 9 shows the DNA sequence (SEQ ID NO: 10) of ro/-6.
- Figure 10 shows the amino acid sequence (SEQ ID NO:l 1) of ro/-6.
- the present invention provides methods and compositions useful for the production and use of transgenic animals.
- the methods and transgenic animals of the invention also provide an efficient and effective system for screening drug effective in ameloriating the effects of toxic gene products.
- the animal used is transparent for at least part of its life cycle, for example, oocytes (Xenopus or others); larvae; pupae, fish (zebrafish or others); and nematodes, such as C. elegans.
- C. elegans is particularly preferred because it is transparent throughout its life and has been extensively studied as a model to determine developmentally regulated gene expression, as well as pattern formation. The visibility of all of the animals' cells throughout their life cycles, has led to the complete determination of the cell lineages, and a detailed description of the morphogenic changes that occur during C. elegans development. Rapid methods for introduction of cloned DNA into the C. elegans germ line has provided means to study molecular function and expression in vivo, as the effects of the gene expression are usually readily visible in the transparent worms.
- the methods and compositions of the present invention make use of reporter genes to monitor gene activity. Visible and quantifiable reporter genes are known and described in the art. Successfully used reporter molecules in gene fusion vectors in studies with C. elegans include the E. coli lac coding region (See e.g., A. Fire et al, (1990) Gene 93: 189- 198), and the Aequora victoria gfp coding region (See e.g., M. Chalfie et al, (1994) Science 263:802-805; D.C. Prasher et al, (1992) Gene 111:229-233; and Genbank Accession #M62654), which produces an intrinsically fluorescent protein.
- E. coli lac coding region See e.g., A. Fire et al, (1990) Gene 93: 189- 198
- the Aequora victoria gfp coding region See e.g., M. Chalfie e
- transgene fusion constructs were developed as an alternative to the lacL markers, but have been available for a much shorter time (See e.g., Chalfie et al, (1994), supra; U.S.
- Patent No. 5,491,084 Initial reports indicate that the fluorescence pattern appears to be more restricted than that exhibited by equivalent lacL fusion. In addition, there are still problems associated with the germline expression of the transgenes and ectopic expression. Indeed, in some cases, the problems with ectopic expression have been exacerbated by these "improvements.”
- the present invention overcomes many of these problems described in the art.
- the tranparent animals and dually transgenic animals described herein provide easily visible, stably expressed systems in which the toxic transgene and reporter gene are expressed similarly to endogenous chromosomal gene expression. These animals provide an excellent system for screening compounds having effects on the toxic transgene.
- the present invention therefore, provides model systems for the study of human diseases and methods of identifying therapeutic compounds using these animal systems.
- the reporter genes are operably linked to an inducible promoter.
- the promoter is induced by the toxic transgene, for example by the gene product of the toxic transgene. It is also contemplated that the toxic transgene can act to induce the promoter indirectly, for example by disrupting other cellular proteins or functions.
- Suitable inducible promoters are available and can be readily determined by those skilled in the art. Non-limiting examples of promoters which are induced by "stresses" include the metallothionein gene promoter (mtl-l or mtl-2; e.g., Genbank Accession #M92910, #M11794, #X00504, and #X00953), and the C.
- elegans amyloid precursor protein (APP) homolog apl-l gene promoter See e.g., Daigle and Li, Proc. Natl. Acad., Sci., 90:12045-12049 [1993]).
- Other potential promoters include those from other inducible heat-shock genes; at least one of the known C. elegans hsplO genes is strongly heat-inducible. It is also contemplated that promoters from genes known to be up- regulated under stress conditions in other systems (e.g., superoxide dismutase, catalase, glutathione reductase, etc.) may also be useful.
- a strong muscle-specific promoter was used to express a potentially secretable form of the ⁇ -peptide, so as to generate significant extracellular levels of ⁇ -peptide. This was accomplished in order to mimic the situation that may exist in the human brain, and allow observations of cell- external neurotoxicity. The present inventor has also demonstrated that the promoter must be chosen so that enough ⁇ -peptide is produced to cause physiological effects, but not so much to kill the animals.
- the wrac-54/ ⁇ -(l-42) minigene was constructed with a modified signal sequence that has been previously shown to allow secretion of a her-l protein product that is ectopically expressed in muscle cells (M.D. Perry et al, (1993) Genes Dev., 7:216-228).
- the development of C. elegans transgenic for expression of ⁇ -amyloid was previously described by the inventor (Link, (1995) Proc. Natl Acad. Sci., 92:9368-9572).
- ⁇ -peptide expression will be directed to other tissues, through utilization of appropriate promoters.
- animals expressing ⁇ -peptide in the intestine may be particularly useful to analyze compounds such as drugs for their effect on ⁇ -peptide, as these cells readily take up exogenous compounds administered orally.
- the transgene element of the present invention can be any sequence which is able to induce the promoter operably linked to the reporter gene.
- the transgene is "toxic" in the sense that it disrupts cellular function in some way.
- the transgene encodes a protein that is toxic to the host cells and/or organism in that it causes deleterious effects to the host, for instance interfering with the hosts ability to survive and/or grow.
- the toxic transgenes encode proteins that disrupt cellular function directly
- the toxic transgene comprises a gene encoding for an amyloidic protein, for example beta amyloid peptide, prion protein variants, transthyretin variants, gelsolin variants, cystatin variants, lysozyme variants and the like.
- the transgene encodes a protein containing polyglutamine resulting from triplet-repeat expansion such as huntingtin (a protein that has been implicated in Huntington's Chorea), ataxin-1 or ataxin-2.
- a protein containing polyglutamine resulting from triplet-repeat expansion such as huntingtin (a protein that has been implicated in Huntington's Chorea), ataxin-1 or ataxin-2.
- proteins associated with inherent amyelotopic lateral sclerosis (ALS) for example, superoxide dismutase 1 variants and over-expressed neurofilament protein, can be used.
- ALS amyelotopic lateral sclerosis
- the transgene can encode for an entire toxic protein or, alternatively, a functional (i.e. toxic) fragment.
- the present invention includes a dually transgenic non-human animal.
- the development of these dually transgenic animals involves the production of two C. elegans lines with a single transgene in each line, designated as CL2005 and CL2070.
- C. elegans was chosen due to the observation that the toxic effect of ⁇ -amyloid has been reported to occur in these animals, in addition to humans.
- Line CL2005 exhibited muscle-specific expression of human ⁇ peptide
- line CL2070 exhibited stress-inducible expression of GFP.
- GFP was incorporated into the present invention as it provides a marker (i.e., "reporter") that is readily visible in living worms.
- dually transgenic animals both express ⁇ -peptide in their muscle cells and under appropriate conditions for observation (i.e., fluorescence microscopy), exhibit green fluorescence in these cells.
- the present invention provides an easily detectable method for the specific expression of ⁇ -peptide in dually transgenic animals. This ease of detection provides great advantages for the development of methods to analyze the effects of ⁇ -amyloid in vivo.
- the dually transgenic animals are not killed in order to detect the presence of ⁇ -amyloid, as would be required if other reporters (e.g., lacL or luciferase) were used, the animals may be useful for screening compounds for their effects on ⁇ -amyloid in an in vivo situation.
- the use of an reporter which is detectable in vivo provides significant advantages over currently available methods.
- the present invention also includes methods of screening compounds for their ability to prevent or inhibit toxicity due to the toxic transgene.
- the methods and animals described above can be used to identify potential therapies.
- transgenic worms e.g., green fluorescing worms with muscle-specific ⁇ -peptide expression
- the animals would no longer glow green.
- the present invention provides a fast and efficient screening system, for example by using commercially available equipment for assaying multiple compounds at once.
- transgenic animals of the present invention expressing a detectable reporter gene triggered by a toxic transgene provide animal models for human diseases.
- a reporter gene such as GFP
- GFP a reporter gene induced by expression of ⁇ -peptide
- the present invention be limited to animals expressing ⁇ -peptide in conjunction with GFP.
- expression of other proteins associated with dementia and/or Alzheimer's or other diseases would also find use in conjunction with GFP in C. elegans as well.
- proteins including mutated versions of proteins
- proteins such as the presenilins associated with Alzheimer's disease (See e.g., J. Marx (1996) Science 274:1838-1840) will be used in conjunction with GFP and full-length APP in dually transgenic C. elegans.
- Other toxic proteins which provide animal models for other human diseases are described herein.
- transgenic animals also provide a means to screen compounds for their ability to decrease or eliminate the toxicity.
- compounds suitable for testing using the transgenic animals of the present invention include, but are not limited to, Congo Red, tumor necrosis factor (TNF), estrogen, tacrine (9-amino-l, 2,3, 4-tetrahydroacri dine), dihydroepiandrosterone (DHEA), compounds that inhibit ApoE4, and others, commercially available from suppliers such as Sigma.
- Compounds to be tested for antitoxic activity are administered to the same number of dually transgenic animals (e.g., generated using the methods described in the Examples, below) from the control group and the treatment group, and the presence or absence of reporter gene used as a measure of efficacy.
- the compounds being tested can be administered using any suitable route (e.g., oral, parenteral, controlled-release transdermal methods, and implants, etc.).
- the compounds to be tested are suspended in the growth media provided to the worms.
- the route of administration will depend on the stability of the compound, the susceptibility of the compound to "first pass" metabolism, the concentration needed to achieve a therapeutic effect, and the like.
- a compound that appears promising i.e., which increases the number of worms which display reduced ⁇ -peptide toxicity
- Another screening method involves the crossing of the transgenic worms of the present invention with other transgenic worms.
- the animals are observed after treatment, in the presence and absence of the test compound(s), with the effects on the toxic transgene being gauged either by crude survival or the presence/absence of the reporter gene.
- the methods of the present invention be modified so as to provide means to analyze disease-related proteins believed to have dominant toxic effects, by substituting appropriate sequences for the ⁇ -peptide sequences used as described in the Examples.
- proteins such as transthyretin (known to be associated with familial amyloid polyneuropathy; See e.g., Christmason et al, (1991) FEBS 281:177-180; Genbank Accession #D00096), and variant superoxide dismutase (known to be associated with familial amyotrophic lateral sclerosis [Lou Gehrig's disease]), prion proteins, A4 amyloid protein (See e.g., Ponte et al, (1988) Nature 331:525-527; Salbaum et al, U.S. Patent No.
- APP See e.g., Kitaguchi et al, (1988) Nature 331:530-532; Sata et al, EP Appln. 94117512.7; Scott et al, WO 9412627; Wadsworth et al, WO 9314200; Gearhart et al, WO 9423049; and Neve et al, WO
- amyloidic proteins e.g., variant lysozymes and amylin peptide
- other proteins associated with neuronal degeneration See e.g., U.S. Patent No. 5,196,333
- animals transgenic for dual proteins e.g., ⁇ -peptide in combination with another protein, such as transthyretin
- the present invention provides the means to analyze the effects of numerous genes and proteins in vivo.
- transgenic animals of the present invention provide distinct advantages over other transgenic animals currently used to analyze diseases such as Alzheimer's disease. Due to the short gestation period of C. elegans, transgenic animals can be produced much more rapidly than when mammals, such as mice are used. For example, transgenic mice overexpressing a 695 amino acid isoform of ⁇ -amyloid precursor did not show learning and memory impairment until they were 9-10 months of age (Hsiao et al, Science 274:99-102 [1996]). In contrast, the transgenic animals of the present invention express ⁇ -peptide and may be manipulated at a very early age, even in embryonic stages.
- transgenic animals are easy to select based on the presence of the green fluorescence, invasive procedures such as surgery, necessary to analyze the effects of the toxic transgene in other animals (e.g., mice) are avoided.
- the present invention provides methods and compositions useful as animal models for disease, as well as providing methods and compositions for disease therapy and prevention.
- the animal testing may be supplemented and confirmed by testing on human subjects.
- the transgenic animals of the present invention allow the testing of a large number of compounds, both various methods, including those known in the art.
- non-human animal includes vertebrates such as rodents, arthropods, insects (e.g., Diptera), fish (e.g., zebrafish), non-human primates, ovines, bovines, ruminants, lagomorphs, porcines, caprines, equines, canines, felines, aves, etc.
- the non- human animal can be used at any stage in its development, for example oocyte, fetal, larval, pupal stages or the like.
- Preferred non-human animals are those that are transparent, such as certain nematodes, oocytes, larvae and fish.
- the term "transparent" is used in references to animals through which light will be transmitted. However, it is not intended that the amount of light transmittance be limited to any particular amount.
- an animal is transparent so long as at least some light may be transmited through its body.
- Non-limiting examples of transparent animals are larval stages of some animals (e.g., flies) and oocytes (e.g., Xenopus oocytes).
- Particularly preferred non-human animals are selected from the nematodes (i.e., any animal in the Class Nematoda), most preferably Caenorhabditis elegans.
- other transparent animals such as zebrafish will be useful in the present invention.
- transgenic zebrafish have been produced (See e.g., Lin et al, PCT Publ. WO9603034; incorporated herein by reference).
- the "non-human animals having a genetically engineered genotype” of the invention are preferably produced by experimental manipulation of the genome of the germline of the non-human animal.
- These genetically engineered non-human animals may be produced by several methods including the introduction of a "transgene” comprising nucleic acid (usually DNA) into an embryonal target cell or integration into a chromosome of the somatic and/or germ line cells of a non-human animal by way of human intervention, such as by the methods described herein.
- transgenic non-human animals The process by which a DNA molecule becomes stably incorporated into another genome is referred to as "stable integration."
- stable integration Non-human animals which contain a transgene are referred to as "transgenic non-human animals”.
- transgenic animal is an animal whose genome has been altered by the introduction of one or more transgenes.
- transgene refers to a foreign gene that is placed into an organism by introducing the foreign gene into gonadal cells, embryonic cells, newly fertilized eggs, or early embryos.
- foreign gene refers to any nucleic acid (e.g., gene sequence) which is introduced into the genome of an animal by experimental manipulations and may include gene sequences found in that animal so long as the introduced gene contains some modification relative to the naturally-occurring gene.
- a preferred foreign gene is the ⁇ -amyloid gene (e.g., ⁇ -peptide), or fragments thereof.
- a "toxic transgene” refers to a foreign gene which disrupts cellular function in some way. For example, the toxic transgene may produce a gene product (i.e., protein) which is toxic to the cell or organism. Alternatively, the transgene may disrupt other cellular proteins, or act as a DNA binding site without producing a protein.
- toxicity refers to the production of toxic effects by any compound or substance.
- ⁇ -peptide toxicity may arise due to the accumulation of ⁇ - peptide molecules.
- toxicity associated with ⁇ -peptide may be manifested as negative effects on muscle cells of dually transgenic animals.
- promoter element refers to a DNA sequence that is located at the 5' end of (i.e., precedes) a gene in a DNA polymer and provides a site for initiation of the transcription of the gene into mRNA.
- inducible promoter is a promoter that is triggered by certain signals within the cell, for instance binding of a transcription factor, stress, heat or the like.
- reporter gene refers to genes that encode proteins or other compounds that can be detected by a variety of methods. These genes "report” the occurrence of successful introduction and expression of sequences such as transgenes.
- Non-limiting examples of reporter genes include antibiotic resistance genes, genes encoding enzymes and genes encoding other detectable proteins. Expression of the reporter gene is detected using methods known in the art.
- the reporter gene is a GFP gene, although lacZ ⁇ -galactosidase gene, or any other reporter system may be used to detect the successful production of transgenic animals.
- the reporter is a compound or protein which may be present or expressed within living animals. That is, it is not necessary to sacrifice the animal in order to detect the presence of the reporter.
- the type of the reporter gene system used is not critical to the invention, and it is contemplated that any system suitable for use with the transgenic animals of the present invention will be used.
- the terms “dual trangenic” and “dually transgenic” refer to animals or cells in which more than one transgene have been introduced.
- the term is used in reference to cells which contain the sequences encoding ⁇ -peptide, and sequences encoding a reporter (e.g., GFP).
- a reporter e.g., GFP
- the number of transgenes in the dually transgenic animals of the present invention be limited to two.
- the transgenic animals may also contain another one or more marker genes (e.g., rol-6 sequences), in addition to ⁇ -peptide and reporter sequences.
- expression of the marker gene is accomplished by observing the living animals for the rolling behavior that results due to the expression of the abnormal collagen gene.
- wild-type animals exhibit normal locomotion and do not exhibit this rolling behavior, as their collagen is normal.
- the transgenic animals of the present invention are preferentially generated by introduction of the targeting vectors into gonad cells.
- Transgenes can be efficiently introduced into the cells by DNA transfection using a variety of methods known to the art, including electroporation, calcium phosphate co-precipitation, protoplast or spheroplast fusion, lipofection, and DEAE-dextran-mediated transfection.
- Transgenes may also be introduced into cells by retrovirus-mediated transduction or by micro-injection.
- the transgenes are injected into gonads of C. elegans as described by Mello et al. (1991) EMBO J., 10:3959-3970.
- transgenic animals containing an altered gene are known to the art. For example, embryonal cells at various developmental stages can be used to introduce transgenes for the production of transgenic animals. Different methods are used depending on the stage of development of the embryonal cell.
- Means for producing labeled hybridization or PCR probes for detecting related sequences include oligolabeling, nick translation, and end-labeling or PCR amplification using a labeled nucleotide.
- Suitable reporter molecules or labels include those radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles and the like.
- the term may also be used in reference to proteins.
- a variety of protocols which employ polyclonal or monoclonal antibodies specific for the ⁇ -peptide protein product are known in the art (See, the Examples). These antibodies can be used as markers for the expression of proteins. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS).
- gene refers to a DNA sequence that comprises coding sequences necessary for the production of a polypeptide or precursor. In some instances, a gene can also include control sequences.
- the polypeptide can be encoded by a full length coding sequence or by any portion of the coding sequence so long as the desired enzymatic activity is retained.
- gene of interest refers to any gene, the manipulation of which may be deemed desirable for any reason, by one of ordinary skill in the art.
- wild-type refers to a gene or gene product which has the characteristics of that gene or gene product when isolated from a naturally occurring source.
- a wild-type gene is that which is most frequently observed in a population and is thus arbitrarily designed the "normal” or “wild-type” form of the gene.
- modified or mutant refers to a gene or gene product which displays modifications in sequence and or functional properties (i.e., altered characteristics) when compared to the wild-type gene or gene product. It is noted that naturally-occurring mutants can be isolated; these are identified by the fact that they have altered characteristics when compared to the wild-type gene or gene product.
- targeting vector or “targeting construct” refer to oligonucleotide sequences comprising a gene of interest flanked on either side by regulatory sequences.
- the targeting vector is capable of homologous recombination such that the gene of interest is integrated by recombination.
- vector and “vehicle” are used interchangeably in reference to nucleic acid molecules that transfer DNA segment(s) from one cell to another.
- expression vector or “expression cassette” as used herein, refers to a recombinant DNA molecule containing a desired coding sequence and appropriate nucleic acid sequences necessary for the expression of the operably linked coding sequence in a particular host organism.
- Nucleic acid sequences necessary for expression in prokaryotes usually include a promoter, an operator (optional), and a ribosome binding site, often along with other sequences.
- Eukaryotic cells are known to utilize promoters, enhancers, and termination and polyadenylation signals.
- operable combination refers to the linkage of nucleic acid sequences in such a manner that a nucleic acid molecule capable of directing the transcription of a given gene and/or the synthesis of a desired protein molecule is produced.
- the term also refers to the linkage of amino acid sequences in such a manner so that a functional protein is produced.
- tissue-type specific refers to a promoter that is capable of selectively directing expression of a gene in a specific tissue.
- tissue-specific promoter in the method of the present invention does not require absolute specificity. In general, the requisite specificity is found where a plurality (or, more preferably, a majority) of cells in one tissue type express a gene of interest, while virtually all (e.g., greater than 80%, and preferably greater than 90%, and more preferably greater than 95%), of the cells in other tissue types do not.
- the strong muscle promoter unc54 was used (See, Example 1).
- portion when in reference to a gene refers to fragments of that gene.
- the fragments may range in size from a few nucleotides to the entire gene sequence minus one nucleotide.
- an oligonucleotide comprising at least a portion of a gene may comprise fragments of the gene or the entire gene.
- substantially purified refers to molecules, either nucleic or amino acid sequences, that are removed from their natural environment, isolated or separated, and are at least 60% free, preferably 75% free, and most preferably 90% free from other components with which they are naturally associated.
- An "isolated polynucleotide” is therefore a substantially purified polynucleotide.
- PCR polymerase chain reaction
- the mixture is denatured and the primers then annealed to their complementary sequences within the target molecule.
- the primers are extended with a polymerase so as to form a new pair of complementary strands.
- the steps of denaturation, primer annealing and polymerase extension can be repeated many times (i.e. , denaturation, annealing and extension constitute one "cycle”; there can be numerous "cycles") to obtain a high concentration of an amplified segment of the desired target sequence.
- the length of the amplified segment of the desired target sequence is determined by the relative positions of the primers with respect to each other, and therefore, this length is a controllable parameter.
- PCR polymerase chain reaction
- PCR it is possible to amplify a single copy of a specific target sequence in genomic DNA to a level detectable by several different methodologies (e.g., hybridization with a labeled probe; incorporation of biotinylated primers followed by avidin-enzyme conjugate detection; and/or incorporation of 32 P-labeled deoxynucleotide triphosphates, such as dCTP or dATP, into the amplified segment).
- any oligonucleotide sequence can be amplified with the appropriate set of primer molecules.
- the amplified segments created by the PCR process itself are, themselves, efficient templates for subsequent PCR amplifications.
- Amplified target sequences may be used to obtain segments of DNA (e.g., genes) for the construction of targeting vectors, transgenes, etc.
- PCR product and “amplification product” refer to the resultant mixture of compounds after two or more cycles of the PCR steps of denaturation, annealing and extension are complete. These terms encompass the case where there has been amplification of one or more segments of one or more target sequences.
- the term "Central Nervous System” refers to the "spinal cord” and the "brain.”
- the spinal cord comprises white areas and grey areas.
- the grey area contains nerve cell bodies, whereas the white area is essentially comprised of myelinated nerves.
- the brain which is also known as the encephalon, is that portion of the cerebrospinal axis which is contained in the cavity of the cranium.
- the brain comprises the two cerebral hemispheres, the inter- brain, the mid-brain, the pons Varolli and cerebellum, and the medulla oblongata.
- the two hemispheres together with the parts derived from the thalamencephalon form the forebrain.
- the two cerebral hemispheres are separated by the longitudinal fissure and also comprise the bylvian fissure, the fissure of Rolando, and the parieto-occipital fissure.
- the lobes on the external surface of the brain comprise the frontal lobe, the parietal lobe, the occipital lobe, and the temporal lobe.
- Placed along the middle line of the brain are, among others, the rostrum and peduncles of corpus callosum, lamina cinera, optic commissure and the pituitary body.
- On each side of the middle line lies the frontal lobe, olfactory lobe and the hemisphere of cerebellum.
- nerve cells are composed of the nerve cell body (perikaryon), one or more dendrites, and an axon. Neurons can be classified according to the number of processes originating from the cell body. Thus, unipolar neurons have a single process, bipolar neurons have one axon and one dendrite, while multipolar neurons (which are the most common) comprise more than two processes.
- nerve comprises cholinergic neurons and sensory neurons.
- cholinergic neuron means a neuron in the Central Nervous System (CNS) and in the Peripheral Nervous System (PNS) whose neurotransmitter is acetylcholine.
- PNS Peripheral Nervous System
- sensor neuron includes a neuron which is responsive to environmental cues (e.g., temperature and movement) from, for example, the skin, muscle and joints of a mammal.
- neural refers to two or more neurons arranged in linear sequence such that the axon of one neuron establishes a structural and functional link with the dendrite of a second neuron to form a "synapse.”
- a compound refers to any chemical entity, pharmaceutical, drug, and the like that can be used to treat or prevent a disease, illness, sickness, or disorder of bodily function.
- Compounds comprise both known and potential therapeutic compounds.
- a compound can be determined to be therapeutic by testing using the testing methods of the present invention (i.e., a "test compound”).
- a "known therapeutic compound” refers to a therapeutic compound that has been shown (e.g., through animal trials or prior experience with administration to humans) to be effective in such treatment or prevention. In other words, a known therapeutic compound is not limited to a compound efficacious in the treatment or prevention of neural related disorders.
- a compound is said to be "in a form suitable for administration such that the compound is bioavailable in the blood of the animal" when the compound may be administered to an animal by any desired route (e.g., oral, intravenous, subcutaneous, intramuscular, etc.) and the compound or its active metabolites appears in the blood of the animal in an active form.
- Administration of a compound to a pregnant animal may result in delivery of bioavailable compound to the embryonic progeny of the animal.
- wild-type ⁇ -amyloid or " ⁇ -peptide” gene and gene product refers to the nucleotide and amino acid sequences provided in SEQ ID NOS:6 and 7, respectively.
- SEQ ID NOS:6 and 7 certain modifications of SEQ ID NOS:6 and 7 can be made which will not interfere with the production of a polypeptide having an activity indistinguishable from that of the wild-type ⁇ -amyloid; the present invention specifically contemplates these variant forms of ⁇ -amyloid.
- a "variant" of the ⁇ -peptide is defined as an amino acid sequence that differs by one or more amino acids.
- the variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties (e.g., replacement of leucine with isoleucine). More rarely, a variant may have "nonconservative" changes, e.g., replacement of a glycine with a tryptophan. Similar minor variations may also include amino acid deletions or insertions (i.e., additions), or both. Guidance in determining which and how many amino acid residues may be substituted, inserted or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, DNAStar software.
- an oligonucleotide sequence comprising at least a portion of a human ⁇ - amyloid gene refers to a polynucleotide sequence (i.e., a nucleic acid sequence) containing a nucleotide sequence derived from a human ⁇ -amyloid gene. This sequence may encode a portion or all of the ⁇ -amyloid protein; alternatively, this sequence may contain non-coding regions derived from the ⁇ -amyloid gene or a combination of coding and non-coding regions.
- the oligonucleotide may be RNA or DNA and may be of genomic or synthetic origin.
- portion when in reference to a gene refers to fragments of that gene.
- the fragments may range in size from 10 nucleotides to the entire gene sequence minus one nucleotide.
- an oligonucleotide comprising at least a portion of a gene may comprise fragments of the gene or the entire gene.
- heterologous marker gene an animal whose genome contains a marker gene not naturally found in the animal's genome.
- the heterologous marker gene is a mutant collagen gene, such as the rol-6 (su- 1006) gene.
- rol-6 ser- 1006 gene.
- other marker genes will be used with success in the present invention, including other mutant collagen genes, as well as other marker genes commonly known to those in the art.
- diagnostic assay refers to methods for the diagnosis of disease, illness, and/or pathology. It is intended that the term encompass any methods for diagnosis, including, but not limited to assays based on immunoreactivity (e.g., radioimmunoassays, fluorescence immunoassays, enzyme immunoassays), histochemistry, dye retention or binding (e.g., fixing of dyes such as Congo Red), nucleic acid based diagnostic methods (e.g., identification of nucleic acid sequences associated with disease or pathology), etc.
- immunoreactivity e.g., radioimmunoassays, fluorescence immunoassays, enzyme immunoassays
- histochemistry e.g., fixing of dyes such as Congo Red
- dye retention or binding e.g., fixing of dyes such as Congo Red
- nucleic acid based diagnostic methods e.g., identification of nucleic acid sequences associated with disease or pathology
- the amplification product was cleaved with Kpnl and Sad, and inserted between the unique Kpnl and Sac I sites of pCL2, to generate "pCL3.”
- the signal peptide/ ⁇ -(l-42) minigene fragment was removed from this plasmid by digestion with Nhel and Sacl, and inserted between the unique Nhel and Sad sites of pPD30.38, to produce "pCL12."
- the sequence of the ⁇ -(l-42) minigene was confirmed by dideoxy DNA sequencing of the coding strand only, by techniques known in the art.
- the sequence of pCL12 (SEQ ID NO:5), is shown in Figure 2.
- a graphic map of pCL12 is provided at Figure 3.
- Figure 4 shows the DNA and amino acid sequences (SEQ ID NOS: 6 and 7, respectively) of pCL12 from nucleotide 1071 through 1253 (i.e., the ⁇ (l-42) nucleic acid and amino acid sequences) present in the construct.
- the expression vector (“pCL25”) containing the hsp/GFP reporter which drives the expression of the GFP-TT gene was constructed.
- This vector was used in subsequent experiments (See, Example 3) to produce transgenic C. elegans was constructed.
- GFP-TT is a modified form of GFP that contains Ser65Thr and Ilel67Thr (the numbering is relative to the sequence of the wild-type GFP). The substitutions present in GFP-TT produce a protein which results in the production of a much brighter fluorescence than the wild-type GFP.
- pCL25 was constructed as described below.
- a 431 bp Hindlll-BamYll fragment containing the hspl6-2 promoter was excised from the plasmid "pPD49.78,” by digestion with BamUl and HmdIII.
- This 431 bp Hindl ⁇ l-BamHl fragment was inserted between the HmdIII (nucleotide #1) and Bam ⁇ l (nucleotide #31) sites of the GFP-TT gene in the plasmid "pGFP-TT,” (available from Yishi Jin, at the University of California, Santa
- the pGFP-TT plasmid contains the coding regions for GFP-TT inserted into a Tu61 backbone.
- the DNA sequence of pGFP-TT (SEQ ID NO: 8) is shown in Figure 5.
- a schematic map of pGFP-TT is shown in Figure 6, in which unique restriction sites are shown.
- the pGFP-TT plasmid was digested with HmdIII and Bam ⁇ l, and the 431 bp fragment containing the hspl6-2 promoter was inserted, in order to generate the stress-inducible expression vector "pCL25.”
- the DNA sequence of pCL25 (SEQ ID NO:9) and restriction map are shown in Figure 7.
- Figure 8 provides a schematic map of pCL25 in which unique restriction sites are shown.
- the transgenic parent animals were produced, with one line expressing the ⁇ (l-42) minigene (designated as "CL2005") and the other line expressing the hsp/GFP reporter (designated as "CL2070").
- the transgenes were introduced into C. elegans by gonad microinjection as known in the art and described by Mello et al. (Mello et EMBO J., 10:3959-3970 [1991]).
- Marker plasmid pRF4 containing the gene (ro/-6 " [sul006]) (SEQ ID NO:9)(pRF4 carries a 4 kb EcoRI fragment of C. elegans genomic DNA containing the r /-6[sul006] collagen gene in the Bluescribe vector
- the (rol-6[sul006J) gene (SEQ ID NO:9), contained within the pRF4 plasmid is a mutated C. elegans collagen gene, the expression of which produces the dominant, distinctive
- Transmitting lines were established and maintained by selection for the Roller marker phenotype.
- Transgenic animals produced in this manner maintain the injected DNA as an extrachromosomal, multicopy array of variable mitotic and meiotic stability.
- Transgenic (i.e., as indicated by the Roller phenotype) animals produce both transgenic (i.e., Roller) and non-transgenic (i.e., non-Roller) progeny. These non- transgenic progeny were found to serve as good internal controls for phenotypic and immunohistochemical comparisons.
- the expression of GFP in the dual transgenic animals can be detected in less than 24 hours after the upshift of animals from 16 to 25.5°C, at all stages of development, from late embryonic to adult. Expression of GFP resulted in the production of green fluorescence in muscle cells; intense tissue-specific expression of GFP was observed.
- the fluorescence can be observed using compound or dissecting epifluoroescence microscopy (i.e., with standard fluorescein excitation and emission filters). It is also contemplated that the fluorescence is observable by use of fluorimeters and cell sorters.
- 5 / ⁇ (l-42) minigene construct contained muscle-specific deposits of anti- ⁇ peptide immunoreactivity.
- Non anti- ⁇ -immunoreactivity was observed in control animals (i.e,, non-transgenic, wild-type C. elegans tested concurrently).
- C. elegans is reported to contain a homolog of the ⁇ -amyloid precursor protein gene (See, Daigle and Li, Proc. Natl. Acad. Sci., 90:2045-2049 [1993]), this sequence does not contain an apparent ⁇ - peptide domain. Thus, it would not be expected, nor did it show, cross-reactivity with the anti- ⁇ antibody used in these experiments.
- immunoreactive deposits accumulated in the body wall of the animals.
- Muscle-specific ⁇ peptide deposits were observed, and showed a qualitative correlation with the level of GFP expression in these muscle cells (i.e., cells that contained more ⁇ -peptide deposits were more green than cells with less ⁇ -peptide deposits).
- Congo Red and Chrysamine G two dyes known to interact with ⁇ - amyloid and have been reported to interfere with its aggregation are tested on the dually transgenic animals.
- Anti-oxidants e.g., vitamin E and ascorbate
- interference with aggregation of ⁇ -peptide, or interaction with ⁇ -amyloid are observed.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Environmental Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to methods and compositions for visualization of the toxic effects of transgenes in vivo. In particular, the present invention provides methods and compositions for the production and use of transgenic, including dually transgenic, Caenorhabditis elegans for visualization of the toxic effects of β-amyloid accumulation in vivo.
Description
BETA-AMYLOID TOXICITY
FIELD OF THE INVENTION The present invention is in the field of medicine and molecular biology. In particular, the invention provides transgenic non-human animals in which expression of a reporter gene is induced by a toxic transgene. The invention also provides methods and compositions for in vivo visualization of the toxicity associated with toxic proteins. In addition, the present invention provides methods and compositions for the production and use of transgenic non-human animals for screening candidate drugs to assess and treat toxicity.
BACKGROUND OF THE INVENTION
Investigation of the molecular mechanisms of various diseases has suggested that many pathologies are caused by expression of proteins that are immediately or gradually deleterious to the cells where they are expressed. Among these diseases are Alzheimer's disease, prion diseases, Huntington's disease, and amyotrophic lateral sclerosis. Several of these diseases are thought to result from aberrant folding of proteins, which results in the accumulation of toxic proteins or protein aggregates.
Alzheimer's disease is associated with the majority of dementia cases in the United States, with an estimated 2 million people afflicted with the disease, and a mortality rate of approximately 100,000 people per year (See, R.W.P. Cutler, "Degenerative and Hereditary
Diseases," in Medicine, Scientific American, New York, (1988), pages 11 (IV):1-13; and R. Katzman (1986) N. Engl J. Med. 314:964). It has been estimated that the total cost for nursing home care alone of Alzheimer's patients exceeds $13 billion/year (See, M.M. Heckler (1985) Am. Psycho! 40:1240). According to the Centers for Disease Control (CDC), mortality due to Alzheimer's disease in the United States increased 10-fold between 1979 and 1987 (0.4 per 100,000 to 4.2 per 100,000) (See, "Reported death rate for Alzheimer's is up tenfold since 1979," (1990) Clin. Psychiatr. News 18:21).
Patients suffering from Alzheimer's disease typically suffer progressive memory deficit, progressive decline in cognitive functions, anxiety, depression, visuospatial and speech deficits, delusions, personality changes, motor skill deterioration, loss of verbal
ability, and incontinence. Eventually, patients are completely incapacitated and disoriented, requiring total care. The course of Alzheimer's disease ranges from less than three years to over 20 years before death occurs. However, in typical cases, it progresses at a fairly constant rate, with an average duration of 6 to 10 years. Alzheimer's disease is not the only cause of dementia. Indeed, there are over fifty recognized causes of dementia. As some causes of dementia are amenable to treatment, differential diagnosis of patients suffering dementia is particularly important. Because at least 20% of clinically diagnosed patients were found at autopsy to have had conditions other than Alzheimer's disease, the National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and Alzheimer's Disease and Related Disorders
Association (ADRDA) refined the clinical diagnostic criteria for Alzheimer's disease (See, M.A. Jenike, "Psychiatry," in Medicine, Scientific American, New York, [1991], pages 13 (V):l-5). Based on these criteria, the diagnosis of Alzheimer's disease may be "definite" (i.e., requiring examination of brain tissue), "probable" (i.e., patients have deficits in two or more areas of cognition, insidious onset of disease, progressive worsening of memory and other cognitive functions, and normal consciousness levels), or "possible" (i.e., patents meet the criteria for probable Alzheimer's disease, but exhibit variations in the disease course or have a systemic illness that is sufficient to cause dementia, but is not considered to be the cause of the dementia). The numerous varieties of dementia, and variations in patient presentations, often make diagnosis problematic. Thus, the NINCDS/ADRDA criteria are very detailed, and necessitate the thorough examination of patients with suspected Alzheimer's disease. Currently, the only way to obtain a definite diagnosis is by post-mortem histological examination of brain tissue for the presence of senile plaques. The histopathological lesions of Alzheimer's disease include neuritic or senile plaques, neurofibrillary degeneration, and granulovacuolar neuronal degeneration. The senile plaques usually contain a core of insoluble, amyloidic extracellular material (" β- amyloid) surrounded by a halo of neurofibrillary tangles and dystrophic neurons. The primary protein component of the amyloidic core of senile plaques is a 4.2 kd amyloid β peptide (often referred to as "Aβ"). A number of other proteins have also been identified
as components of senile plaques, including anti-chymotrypsin and apolipoprotein E. The major component of the neurofibrillary tangles is an abnormally phosphorylated microtubule-associated protein referred to as "tau." The β-amyloid protein in senile plaques is a small glycoprotein (i.e., a 39-43 amino acid protein, derived from the larger amyloid precursor protein), that has been detected in non-neural tissues (e.g., skin, subcutaneous tissue, and intestines) and blood vessels of Alzheimer's disease patients (See, Cutler, supra). Deposits of amyloid may be detected by their ability to bind specific dyes, such as Congo red or thioflavin S. Thus, it has been further hypothesized that detection of this protein may serve as a potential diagnostic aid in the assessment of patients suffering from dementia.
Alzheimer's disease usually arises spontaneously, although genetics play a role in development of the disease. For example, the histopathologic lesions of Alzheimer's disease have been regularly observed in the brains of older patients dying of Down's syndrome (See, Cutler, supra). It is known that the β-amyloid gene resides on chromosome 21. As Down's patients have an extra copy of this chromosome, there is an increased expression of this chromosome in these patients. It has been hypothesized that increased expression of the β-amyloid gene may regulate the formation of amyloid plaques ("senile plaques") in these patients. In addition, four loci were recently identified as playing a role in the genetic susceptibility of Alzheimer's disease (See, Pericak-Vance and Haines (1995) Trends Genet. 11:504).
Other potential risk factors for the development of Alzheimer's disease include environmental factors (e.g., head trauma, smoking, and exposure to heavy metals), sociological factors (e.g., depression and educational level), biological factors (e.g., increasing age and hyperthyroidism), and a family history of Alzheimer's disease, Down's syndrome, or Parkinson's disease (See, Pericak-Vance and Haines, supra). Nonetheless, despite recent advances, the exact etiology and pathogenesis of Alzheimer's disease remain largely unknown.
In addition to the problems associated with diagnosing Alzheimer's disease, improvements are needed in the area of treatment. Many agents have been tested for their ability to treat the cognitive decline associated with Alzheimer's disease. For example,
various cholinergic enhancers (e.g., choline and lecithin) have been tested. Unfortunately, cholinergic precursors have been shown to be not useful, although some drugs that stimulate cholinergic transmission may be helpful in some patients. One example is physostigmine, a compound that prevents the synaptic breakdown of acetylcholine. However, the overall clinical effect of this drug has not been as dramatic as initially hoped
(See, M.A. Jenike, "Psychiatry," in Medicine, Scientific American, New York, (1991), pages 13 (V): 1-5).
Other drugs, such as tetrahydroaminoacridine (THA or tacrine), a centrally acting anti-cholinesterase, have been tested. In a large multi-center trial of THA, liver enzyme abnormalities were reported and the preliminary results indicated that, at least at low dosages, THA is not an effective treatment of Alzheimer's disease (Jenike, supra). Ergoloid mesylates (Hydergine) is an extremely safe compound, and remains the most commonly prescribed drug for patients with Alzheimer's disease. However, the overall effects of the drug are at best minimal. The mechanisms of toxicity due to accumulation of β-peptide are currently the subject of much investigation, and no definitive causes of toxicity have yet been established. (See, Benzi and Moretti (1995) Neurobiology of Aging, 16:661-674). Because of this uncertainty, efforts to develop mechanism-based treatment regimens have not been possible. Compounds presently in use to treat Alzheimer's disease only serve to alleviate the systemic effects associated with the disease.
In order to study disease mechanisms and genetic-based phenomena, animals in which a foreign gene has been inserted have been described by various researchers. International Patent Application WO 96/03034 describes insertion of retroviral vectors into fish, in order to produce fish with desirable traits or to study development. Various transgenic animal models for Alzheimer's disease are described in International Patent
Applications WO 93/14200, WO 93/02189, WO 94/12627, WO 94/23049, and European Patent Publication EP 653154. Typically these transgenic animals are mice or other mammals; however, β-amyloid peptide has been expressed in the nematode Caenorhabditis elegans (Link (1995) Proc. Natl Acad. Sci. 92: 9368). The use of C. elegans for investigation of mutant forms of the C. elegans genes mec-4 and deg-1, which
cause neurodegeneration, is described in U.S. Patent No. 5,196,333. Drawbacks to mammalian animals as model systems are the relatively long generation time, which makes mammals less desirable for high-throughput screening of potential pharmaceuticals, and the difficulty in studying the molecular processes of interest without sacrificing the animal for cell and tissue analysis.
Reporter genes are genes that encode proteins or other compounds that can be detected by a variety of methods, and which "report" the occurrence of successful introduction and expression of gene sequences, β-galactosidase and luciferase are examples of such reporter genes. Recently, the gene for green fluorescent protein (GFP) of the jellyfish Aequorea victoria has been described in U.S. Patent No. 5,491 ,084. This gene can provide a method for indicating expression of a gene via fluorescent detection of GFP. The drawback to using GFP in mammalian systems is as described above, that is, the need to sacrifice the mammal in order to analyze the cells and tissues of interest. This drawback is especially severe in the context of large-scale screening of potential therapeutic compounds, and U.S. Patent No. 5,491,084 does not describe a system suitable for high- throughput screening of pharmaceuticals for activity against toxic proteins expressed in cells.
Thus, methods and animal systems are needed to screen drugs quickly and inexpensively for their effects on proteins and other substances associated with Alzheimer's disease. Convenient methods and animal systems for screening drugs for other neurodegenerative diseases, such as prion diseases, Huntington's disease, and amyotrophic lateral sclerosis, are also desirable.
SUMMARY OF THE INVENTION The present invention provides methods and compositions useful for the production and use of dually transgenic animals, in particular Caenorhabditis elegans. In addition, in one embodiment, the present invention provides transparent animals that express a reporter gene inducible by a toxic transgene. In a preferred embodiment, the toxic transgene encodes β-peptide. Although it is not intended that the present invention be limited to any particular reporter, in a preferred embodiment, the reporter gene is green fluorescence
protein (GFP). It is contemplated that the effects or product of the reporter gene be observable (i.e., the reporter gene is expressed). For example, in embodiments in which GFP is the reporter, its presence is detected using fluorescence microscopy. In addition, in these embodiments, the animals do not need to be sacrificed in order to observe the expression of the reporter gene (i.e., the detection may be accomplished on living animals).
If other reporters are used, other detection methods may be necessary. For example, lacZ expression may be detected by exposing the tissues of the animal to the substrate for the gene (i.e., β-galactoside), and observing for the presence of blue dye in the tissues. However, this method requires that the animal be sacrificed in order to observe the expression of the reporter gene.
In one alternate embodiment, the genome of the transparent animal further contains a heterologous marker gene. In a preferred embodiment, the marker gene is rol-6(su- 1006). In the embodiments in which rol-6(su-1006), expression of the marker gene is accomplished by observing the living animals for the rolling behavior that results due to the expression of the abnormal collagen gene. In contrast, wild-type animals exhibit normal locomotion and do not exhibit this rolling behavior, as their collagen is normal.
In an alternative embodiment, the first transgene of the dually transgenic non- human animal comprises pCL25. In another alternative embodiment, the second transgene of the dually transgenic non-human animal comprises pCL12. In one alternate embodiment, the genome of the transparent animal further contains a heterologous marker gene. In a preferred embodiment, the marker gene is rol-6(su-1006). In the embodiments in which rol-6(su-1006), expression of the marker gene is accomplished by observing the living animals for the rolling behavior that results due to the expression of the abnormal collagen gene. In contrast, wild-type animals exhibit normal locomotion and do not exhibit this rolling behavior, as their collagen is normal.
In a preferred embodiment, the transparent animal is selected from the class Nematoda. Although it is not intended that the transparent animal of the present invention be limited to any specific animal, in a particularly preferred embodiment, the transparent animal is Caenorhabditis elegans.
In an alternate embodiment the cells of the transparent animal display toxicity resulting from the accumulation of β-peptide within the cells. In one preferred embodiment, the genome of the transparent animal comprises SEQ ID NO: 5 and SEQ ID NO:8. The present invention also provides methods for producing dually transgenic non- human animal comprising: providing: a first and second non-human animal; a first transgene comprising β-peptide; and a second transgene, comprising a reporter; introducing the first transgene into the genome of the first non-human animal to produce a first transgenic animal, and introducing the second transgene into the genome of the second non-human animal to produce a second transgenic animal; and mating the first transgenic animal with the second transgenic animal to produce a dually transgenic animal, wherein the β-peptide and the reporter are expressed.
In one embodiment of the methods of the present invention the dually transgenic non-human animal is transparent. In a preferred embodiment, the transparent animal is a nematode, while in a particularly preferred embodiment, the animal is Caenorhabditis elegans.
In an alternative embodiment, the first transgene of the dually transgenic non- human animal comprises pCL25. In another alternative embodiment, the second transgene of the dually transgenic non-human animal comprises pCL12. In one alternate embodiment, the genome of the transparent animal further contains a heterologous marker gene. In a preferred embodiment, the marker gene is rol-6(su-1006). In the embodiments in which rol-6(su-1006), expression of the marker gene is accomplished by observing the living animals for the rolling behavior that results due to the expression of the abnormal collagen gene. In contrast, wild-type animals exhibit normal locomotion and do not exhibit this rolling behavior, as their collagen is normal.
The present invention also comprises methods for testing compounds for anti-toxic effects, comprising: providing a dually transgenic non-human animal expressing a toxic transgene and a reporter; a composition comprising a test compound in a form suitable for administration such that the compound is bioavailable in the cells of the animal; and administering the test compound to the non-human animal. The toxic transgene induces
expression of the reporter gene. In a preferred embodiment, the toxic transgene is β- peptide and the reporter gene is GFP. In one embodiment, the method further comprises the step of measuring a reduction or increase in the expression of the reporter by the dually transgenic non-human animal and thereby identifying a compound as therapeutic. In a particularly preferred embodiment of the methods, the compounds inactivate the β-peptide expressed by the dually transgenic animal.
In one embodiment of the methods for testing compounds for β-peptide toxicity, the dually transgenic non-human animal is transparent. In a preferred embodiment, the transparent animal is a nematode, while in a particularly preferred embodiment, the animal is Caenorhabditis elegans. In an alternative embodiment, the first transgene of the dually transgenic non-human animal comprises pCL25. In another alternative embodiment, the second transgene of the dually transgenic non-human animal comprises pCL12. In one alternate embodiment, the genome of the transparent animal further contains a heterologous marker gene. In a preferred embodiment, the marker gene is rol-6(su-1006), which produces effects described herein.
In one alternative embodiment, one or more test compounds are tested for their ability to counter the toxic effects of transgene product. It is also contemplated that the test compounds will be tested for their ability to prevent the expression of the toxic transgene, for example, β-peptide. In alternative embodiments, dually transgenic animals in which the expression of, or effects of transgene toxicity, are reduced or eliminated by the test compounds, are mated. The progeny of these matings are also then tested for the effects of test compounds on the expression of, or effects of toxicity. In yet another embodiment, the progeny of these matings are used in other assay systems for the identification of therapeutic compounds.
In yet another alternative embodiment, the dually transgenic animals of the present invention are used to identify methods suitable for the diagnostic testing of Alzheimer's disease or pathology due to other diseases. Thus, the dually transgenic animals of the present invention are used to develop assays suitable for use in humans or animal models of Alzheimer's disease.
DESCRIPTION OF THE FIGURES Figure 1 is a diagram illustrating the construction of dual transgenic animals expressing β-amyloid peptide and an hsp/GFP reporter. Figure 2 shows the DNA sequence (SEQ ID NO:5) and restriction map for pCL12.
Figure 3 is a graphic map of pCL12.
Figure 4 shows the DNA (SEQ ID NO:6), and amino acid sequence (SEQ ID NO:7) of pCL12 from nucleotide 1071 through 1253 (i.e., the β-(l-42) nucleic acid and amino acid sequence). Figure 5 shows the DNA sequence (SEQ ID NO: 8) and restriction map for pGFP-
TT.
Figure 6 is a graphic map of pGFP-TT.
Figure 7 shows the DNA sequence (SEQ ID NO:9) and restriction map for pCL25. Figure 8 is a graphic map of pCL25. Figure 9 shows the DNA sequence (SEQ ID NO: 10) of ro/-6.
Figure 10 shows the amino acid sequence (SEQ ID NO:l 1) of ro/-6.
DESCRIPTION OF THE INVENTION The present invention provides methods and compositions useful for the production and use of transgenic animals. The methods and transgenic animals of the invention also provide an efficient and effective system for screening drug effective in ameloriating the effects of toxic gene products.
The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, cell biology and recombinant
DNA, which are within the skill of the art. See, e.g., Sambrook, Fritsch, and Maniatis, MOLECULAR CLONING: A LABORATORY MANUAL, 2nd edition (1989); CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, (F.M. Ausubel et al. eds., 1987); the series METHODS IN ENZYMOLOGY (Academic Press, Inc.); PCR 2: A PRACTICAL APPROACH (M.J. McPherson, B.D. Hames and G.R. Taylor eds., 1995); ANIMAL CELL CULTURE (R.I.
Freshney. Ed., 1987); and ANTIBODIES: A LABORATORY MANUAL (Harlow et al. eds., 1987).
Animals The methods and systems described herein can be practiced with any non-human animal. In a preferred embodiment, the animal used is transparent for at least part of its life cycle, for example, oocytes (Xenopus or others); larvae; pupae, fish (zebrafish or others); and nematodes, such as C. elegans. C. elegans is particularly preferred because it is transparent throughout its life and has been extensively studied as a model to determine developmentally regulated gene expression, as well as pattern formation. The visibility of all of the animals' cells throughout their life cycles, has led to the complete determination of the cell lineages, and a detailed description of the morphogenic changes that occur during C. elegans development. Rapid methods for introduction of cloned DNA into the C. elegans germ line has provided means to study molecular function and expression in vivo, as the effects of the gene expression are usually readily visible in the transparent worms.
Reporter Molecules
The methods and compositions of the present invention make use of reporter genes to monitor gene activity. Visible and quantifiable reporter genes are known and described in the art. Successfully used reporter molecules in gene fusion vectors in studies with C. elegans include the E. coli lac coding region (See e.g., A. Fire et al, (1990) Gene 93: 189- 198), and the Aequora victoria gfp coding region (See e.g., M. Chalfie et al, (1994) Science 263:802-805; D.C. Prasher et al, (1992) Gene 111:229-233; and Genbank Accession #M62654), which produces an intrinsically fluorescent protein. Although various fusion expression vectors have been used and reported in the literature, problems have been encountered (See e.g., A. Fire, "Fire Lab Vector Kit"— June 1995). For example, with lacL, there have been many reports in which it was not possible to correlate transgene expression patterns with physiological expectations, or only weak correlations have been possible. Ectopic expression is often frequently seen with short promoters, and occurs
most prominently in the gut and pharynx of the affected animals. This may be due to weak promoter and/or enhancer signals in the vectors. Expression pattern deficits oflacZ fusions have been classified into three groups. In the first, transgenes are expressed in the correct tissue, but mosaic expression is observed (i.e., only a subset of the cells stain during the detection methods). This has been observed even with integrated high-copy transgenes. In the second group, expression in a single tissue or cell population is not seen with the transgene. Finally, there has been the failure of transgene fusion constructs to show expression in the pre-12 cell embryo, or in any embryonic, larval, or adult germ line. The gfp fusion vectors were developed as an alternative to the lacL markers, but have been available for a much shorter time (See e.g., Chalfie et al, (1994), supra; U.S.
Patent No. 5,491,084). Initial reports indicate that the fluorescence pattern appears to be more restricted than that exhibited by equivalent lacL fusion. In addition, there are still problems associated with the germline expression of the transgenes and ectopic expression. Indeed, in some cases, the problems with ectopic expression have been exacerbated by these "improvements."
The present invention overcomes many of these problems described in the art. The tranparent animals and dually transgenic animals described herein provide easily visible, stably expressed systems in which the toxic transgene and reporter gene are expressed similarly to endogenous chromosomal gene expression. These animals provide an excellent system for screening compounds having effects on the toxic transgene. The present invention, therefore, provides model systems for the study of human diseases and methods of identifying therapeutic compounds using these animal systems.
Inducible Promoters As discussed above, the reporter genes are operably linked to an inducible promoter. The promoter is induced by the toxic transgene, for example by the gene product of the toxic transgene. It is also contemplated that the toxic transgene can act to induce the promoter indirectly, for example by disrupting other cellular proteins or functions. Suitable inducible promoters are available and can be readily determined by those skilled in the art. Non-limiting examples of promoters which are induced by
"stresses" include the metallothionein gene promoter (mtl-l or mtl-2; e.g., Genbank Accession #M92910, #M11794, #X00504, and #X00953), and the C. elegans amyloid precursor protein (APP) homolog apl-l gene promoter (See e.g., Daigle and Li, Proc. Natl. Acad., Sci., 90:12045-12049 [1993]). Other potential promoters include those from other inducible heat-shock genes; at least one of the known C. elegans hsplO genes is strongly heat-inducible. It is also contemplated that promoters from genes known to be up- regulated under stress conditions in other systems (e.g., superoxide dismutase, catalase, glutathione reductase, etc.) may also be useful.
In one embodiment, as described in the Examples below, a strong muscle-specific promoter was used to express a potentially secretable form of the β-peptide, so as to generate significant extracellular levels of β-peptide. This was accomplished in order to mimic the situation that may exist in the human brain, and allow observations of cell- external neurotoxicity. The present inventor has also demonstrated that the promoter must be chosen so that enough β-peptide is produced to cause physiological effects, but not so much to kill the animals.
The wrac-54/β-(l-42) minigene was constructed with a modified signal sequence that has been previously shown to allow secretion of a her-l protein product that is ectopically expressed in muscle cells (M.D. Perry et al, (1993) Genes Dev., 7:216-228). The development of C. elegans transgenic for expression of β-amyloid was previously described by the inventor (Link, (1995) Proc. Natl Acad. Sci., 92:9368-9572).
However, in early experiments, it was observed that β-peptide deposits were not convincingly detected outside of the muscle cells, when tested with the antibodies described in Example 4, below. While an understanding of the mechanism is not necessary for the practice of the present invention, it is apparent that the majority of β- peptide expressed by the transgenic worms is retained in the muscle cells and is responsible for the pathology observed in the muscle cells.
It is also contemplated that β-peptide expression will be directed to other tissues, through utilization of appropriate promoters. For example, it is contemplated that animals expressing β-peptide in the intestine may be particularly useful to analyze compounds such
as drugs for their effect on β-peptide, as these cells readily take up exogenous compounds administered orally.
Transgenes The transgene element of the present invention can be any sequence which is able to induce the promoter operably linked to the reporter gene. As noted, the transgene is "toxic" in the sense that it disrupts cellular function in some way. Preferably, the transgene encodes a protein that is toxic to the host cells and/or organism in that it causes deleterious effects to the host, for instance interfering with the hosts ability to survive and/or grow. The toxic transgenes encode proteins that disrupt cellular function directly
(e.g., the gene product is toxic) or indirectly (e.g., the sequence of the transgene disrupts cellular function by some mechanism other than its gene product). Toxic proteins are distinguishable from simple chemical toxins (e.g., heavy metals and the like) by their antigenicity and higher molecular weight. In one embodiment, the toxic transgene comprises a gene encoding for an amyloidic protein, for example beta amyloid peptide, prion protein variants, transthyretin variants, gelsolin variants, cystatin variants, lysozyme variants and the like. In another embodiment, the transgene encodes a protein containing polyglutamine resulting from triplet-repeat expansion such as huntingtin (a protein that has been implicated in Huntington's Chorea), ataxin-1 or ataxin-2. Alternatively, proteins associated with inherent amyelotopic lateral sclerosis (ALS) for example, superoxide dismutase 1 variants and over-expressed neurofilament protein, can be used. It will be understood that the transgene can encode for an entire toxic protein or, alternatively, a functional (i.e. toxic) fragment.
Transgenic Animals
In one aspect, the present invention includes a dually transgenic non-human animal. In one embodiment, the development of these dually transgenic animals involves the production of two C. elegans lines with a single transgene in each line, designated as CL2005 and CL2070. C. elegans was chosen due to the observation that the toxic effect of
β-amyloid has been reported to occur in these animals, in addition to humans. Line CL2005 exhibited muscle-specific expression of human β peptide, while line CL2070 exhibited stress-inducible expression of GFP. GFP was incorporated into the present invention as it provides a marker (i.e., "reporter") that is readily visible in living worms. Thus, dually transgenic animals both express β-peptide in their muscle cells and under appropriate conditions for observation (i.e., fluorescence microscopy), exhibit green fluorescence in these cells.
Mating of these lines resulted in the production of dually transgenic animals, in which the presence of β-amyloid was easy to detect, due to the fact that the dually transgenic animals expressing β-amyloid glowed green. Thus, the present invention provides an easily detectable method for the specific expression of β-peptide in dually transgenic animals. This ease of detection provides great advantages for the development of methods to analyze the effects of β-amyloid in vivo. In addition, because the dually transgenic animals are not killed in order to detect the presence of β-amyloid, as would be required if other reporters (e.g., lacL or luciferase) were used, the animals may be useful for screening compounds for their effects on β-amyloid in an in vivo situation. Thus, the use of an reporter which is detectable in vivo provides significant advantages over currently available methods.
Other Advantages of Transgenic C. elegans
The present invention also includes methods of screening compounds for their ability to prevent or inhibit toxicity due to the toxic transgene. In these drug screening embodiments, the methods and animals described above can be used to identify potential therapies. For example, in assays to develop compounds to block the expression of β- amyloid or counter its toxic effects, transgenic worms (e.g., green fluorescing worms with muscle-specific β-peptide expression), would be observed for their loss of fluorescence. In assays where the compound is effective in countering the expression of β-peptide or effects of β-peptide, the animals would no longer glow green. It is easy to visually screen and quantify (using commercially available equipment) for animals that have lost the ability to glow, and then use them to detail the interaction between the compound and the toxic
transgene. The present invention provides a fast and efficient screening system, for example by using commercially available equipment for assaying multiple compounds at once.
Thus, the transgenic animals of the present invention expressing a detectable reporter gene triggered by a toxic transgene provide animal models for human diseases.
For instance, a reporter gene (such as GFP) induced by expression of β-peptide provides an animal model for human Alzheimer's disease. It is also not intended that the present invention be limited to animals expressing β-peptide in conjunction with GFP. It is contemplated that expression of other proteins associated with dementia and/or Alzheimer's or other diseases would also find use in conjunction with GFP in C. elegans as well. For example, it is contemplated that proteins (including mutated versions of proteins) such as the presenilins associated with Alzheimer's disease (See e.g., J. Marx (1996) Science 274:1838-1840) will be used in conjunction with GFP and full-length APP in dually transgenic C. elegans. Other toxic proteins which provide animal models for other human diseases are described herein.
These transgenic animals also provide a means to screen compounds for their ability to decrease or eliminate the toxicity. Examples of compounds suitable for testing using the transgenic animals of the present invention include, but are not limited to, Congo Red, tumor necrosis factor (TNF), estrogen, tacrine (9-amino-l, 2,3, 4-tetrahydroacri dine), dihydroepiandrosterone (DHEA), compounds that inhibit ApoE4, and others, commercially available from suppliers such as Sigma. Compounds to be tested for antitoxic activity are administered to the same number of dually transgenic animals (e.g., generated using the methods described in the Examples, below) from the control group and the treatment group, and the presence or absence of reporter gene used as a measure of efficacy.
The compounds being tested can be administered using any suitable route (e.g., oral, parenteral, controlled-release transdermal methods, and implants, etc.). In one preferred route, the compounds to be tested are suspended in the growth media provided to the worms. Generally speaking, the route of administration will depend on the stability of the compound, the susceptibility of the compound to "first pass" metabolism, the
concentration needed to achieve a therapeutic effect, and the like. Following initial screening, a compound that appears promising (i.e., which increases the number of worms which display reduced β-peptide toxicity) is further evaluated by administering various concentrations of the compound to additional transgenic animals in order to determine an approximate therapeutic dosing range.
Another screening method involves the crossing of the transgenic worms of the present invention with other transgenic worms. The animals are observed after treatment, in the presence and absence of the test compound(s), with the effects on the toxic transgene being gauged either by crude survival or the presence/absence of the reporter gene. It is also contemplated that the methods of the present invention be modified so as to provide means to analyze disease-related proteins believed to have dominant toxic effects, by substituting appropriate sequences for the β-peptide sequences used as described in the Examples. For example, proteins such as transthyretin (known to be associated with familial amyloid polyneuropathy; See e.g., Christmason et al, (1991) FEBS 281:177-180; Genbank Accession #D00096), and variant superoxide dismutase (known to be associated with familial amyotrophic lateral sclerosis [Lou Gehrig's disease]), prion proteins, A4 amyloid protein (See e.g., Ponte et al, (1988) Nature 331:525-527; Salbaum et al, U.S. Patent No. 5,151,508, herein incorporated by reference), APP (See e.g., Kitaguchi et al, (1988) Nature 331:530-532; Sata et al, EP Appln. 94117512.7; Scott et al, WO 9412627; Wadsworth et al, WO 9314200; Gearhart et al, WO 9423049; and Neve et al, WO
9302189, all of which are herein incorporated by reference), other amyloidic proteins (e.g., variant lysozymes and amylin peptide), and other proteins associated with neuronal degeneration (See e.g., U.S. Patent No. 5,196,333), will be used in the methods of the present invention by substituting the appropriate nucleic acid sequences encoding the protein of interest for the β-peptide described in Example 1. It is also contemplated that animals transgenic for dual proteins (e.g., β-peptide in combination with another protein, such as transthyretin) will be used. Thus, the present invention provides the means to analyze the effects of numerous genes and proteins in vivo.
Furthermore, the transgenic animals of the present invention provide distinct advantages over other transgenic animals currently used to analyze diseases such as
Alzheimer's disease. Due to the short gestation period of C. elegans, transgenic animals can be produced much more rapidly than when mammals, such as mice are used. For example, transgenic mice overexpressing a 695 amino acid isoform of β-amyloid precursor did not show learning and memory impairment until they were 9-10 months of age (Hsiao et al, Science 274:99-102 [1996]). In contrast, the transgenic animals of the present invention express β-peptide and may be manipulated at a very early age, even in embryonic stages.
In addition, because the transgenic animals are easy to select based on the presence of the green fluorescence, invasive procedures such as surgery, necessary to analyze the effects of the toxic transgene in other animals (e.g., mice) are avoided.
Finally, the apparent toxicity of β-peptide in transgenic animals was found to be temperature-dependent. Transgenic animals maintained at 25.5°C were significantly more sick than those maintained at 16°C. The animals maintained at the higher temperature became paralyzed more quickly, failed to eat or grow, failed to show normal egg-laying, and many died before reaching adulthood. However, wild-type animals grow well at either of these temperatures. The CL2005 parental line was temperature-sensitive for viability, as it was not possible to propagate this line at the elevated temperature. In the CL2070 parental line, 25.5°C maintenance was not sufficient to induce the hsp/GFP construct. The hsp/GFP response was similarly temperature-dependent. It was difficult to detect GFP when the dual transgenic animals were raised at 16°C, but GFP induction was dramatic when the animals were raised at 25.5°C.
These temperature dependency observations were exploited by the propagation of animals at 16°C, and then upshifting them to 25.5°C, when GFP induction was desired. This effect also has potential benefits in the analysis of compounds, as the animals can be pre-incubated in the presence of drugs or other compounds at the lower temperature before the upshift to the higher temperature, in order to ensure that the presumed protective effect of the drug was in place, prior to the strong induction of β-peptide toxicity. Importantly, these assays may be completed within one day and are suitable for rapid methods (e.g., the use of a microtiter format and a plate fluorimeter), so that literally thousands of compounds may be tested simultaneously.
In sum, the present invention provides methods and compositions useful as animal models for disease, as well as providing methods and compositions for disease therapy and prevention. The animal testing may be supplemented and confirmed by testing on human subjects. However, the transgenic animals of the present invention allow the testing of a large number of compounds, both various methods, including those known in the art.
DEFINITIONS To facilitate understanding of the invention, a number of terms are defined below. The term "non-human animal" includes vertebrates such as rodents, arthropods, insects (e.g., Diptera), fish (e.g., zebrafish), non-human primates, ovines, bovines, ruminants, lagomorphs, porcines, caprines, equines, canines, felines, aves, etc. The non- human animal can be used at any stage in its development, for example oocyte, fetal, larval, pupal stages or the like. Preferred non-human animals are those that are transparent, such as certain nematodes, oocytes, larvae and fish. As used herein, the term "transparent" is used in references to animals through which light will be transmitted. However, it is not intended that the amount of light transmittance be limited to any particular amount. For example, an animal is transparent so long as at least some light may be transmited through its body. Non-limiting examples of transparent animals are larval stages of some animals (e.g., flies) and oocytes (e.g., Xenopus oocytes). Particularly preferred non-human animals are selected from the nematodes (i.e., any animal in the Class Nematoda), most preferably Caenorhabditis elegans. However, it is contemplated that other transparent animals, such as zebrafish will be useful in the present invention. For example, transgenic zebrafish have been produced (See e.g., Lin et al, PCT Publ. WO9603034; incorporated herein by reference). The "non-human animals having a genetically engineered genotype" of the invention are preferably produced by experimental manipulation of the genome of the germline of the non-human animal. These genetically engineered non-human animals may be produced by several methods including the introduction of a "transgene" comprising nucleic acid (usually DNA) into an embryonal target cell or integration into a chromosome of the somatic and/or germ line cells of a non-human animal by way of human
intervention, such as by the methods described herein. The process by which a DNA molecule becomes stably incorporated into another genome is referred to as "stable integration." Non-human animals which contain a transgene are referred to as "transgenic non-human animals". A transgenic animal is an animal whose genome has been altered by the introduction of one or more transgenes.
The term "transgene" as used herein refers to a foreign gene that is placed into an organism by introducing the foreign gene into gonadal cells, embryonic cells, newly fertilized eggs, or early embryos. The term "foreign gene" refers to any nucleic acid (e.g., gene sequence) which is introduced into the genome of an animal by experimental manipulations and may include gene sequences found in that animal so long as the introduced gene contains some modification relative to the naturally-occurring gene. A preferred foreign gene is the β-amyloid gene (e.g., β-peptide), or fragments thereof. A "toxic transgene" refers to a foreign gene which disrupts cellular function in some way. For example, the toxic transgene may produce a gene product (i.e., protein) which is toxic to the cell or organism. Alternatively, the transgene may disrupt other cellular proteins, or act as a DNA binding site without producing a protein.
As used herein, the term "toxicity" refers to the production of toxic effects by any compound or substance. For example, while it is not necessary to the understanding and use of the present invention, β-peptide toxicity may arise due to the accumulation of β- peptide molecules. There are numerous manifestations of toxicity that may occur. For example, the toxicity associated with β-peptide may be manifested as negative effects on muscle cells of dually transgenic animals.
The terms "promoter element, " "promoter," or "promoter sequence" as used herein, refer to a DNA sequence that is located at the 5' end of (i.e., precedes) a gene in a DNA polymer and provides a site for initiation of the transcription of the gene into mRNA. An
"inducible promoter" is a promoter that is triggered by certain signals within the cell, for instance binding of a transcription factor, stress, heat or the like.
The term "reporter gene" as used herein refers to genes that encode proteins or other compounds that can be detected by a variety of methods. These genes "report" the occurrence of successful introduction and expression of sequences such as transgenes.
Non-limiting examples of reporter genes include antibiotic resistance genes, genes encoding enzymes and genes encoding other detectable proteins. Expression of the reporter gene is detected using methods known in the art. In a preferred embodiment, the reporter gene is a GFP gene, although lacZ β-galactosidase gene, or any other reporter system may be used to detect the successful production of transgenic animals. In particularly preferred embodiments, the reporter is a compound or protein which may be present or expressed within living animals. That is, it is not necessary to sacrifice the animal in order to detect the presence of the reporter. The type of the reporter gene system used is not critical to the invention, and it is contemplated that any system suitable for use with the transgenic animals of the present invention will be used.
As used herein, the terms "dual trangenic" and "dually transgenic" refer to animals or cells in which more than one transgene have been introduced. For example, the term is used in reference to cells which contain the sequences encoding β-peptide, and sequences encoding a reporter (e.g., GFP). However, it is not intended that the number of transgenes in the dually transgenic animals of the present invention be limited to two. For example, the transgenic animals may also contain another one or more marker genes (e.g., rol-6 sequences), in addition to β-peptide and reporter sequences. In the embodiments in which rol-6 (su- 1006), expression of the marker gene is accomplished by observing the living animals for the rolling behavior that results due to the expression of the abnormal collagen gene. In contrast, wild-type animals exhibit normal locomotion and do not exhibit this rolling behavior, as their collagen is normal.
The transgenic animals of the present invention are preferentially generated by introduction of the targeting vectors into gonad cells. Transgenes can be efficiently introduced into the cells by DNA transfection using a variety of methods known to the art, including electroporation, calcium phosphate co-precipitation, protoplast or spheroplast fusion, lipofection, and DEAE-dextran-mediated transfection. Transgenes may also be introduced into cells by retrovirus-mediated transduction or by micro-injection. In one preferred embodiment, the transgenes are injected into gonads of C. elegans as described by Mello et al. (1991) EMBO J., 10:3959-3970. Alternative methods for the generation of transgenic animals containing an altered gene are known to the art. For example,
embryonal cells at various developmental stages can be used to introduce transgenes for the production of transgenic animals. Different methods are used depending on the stage of development of the embryonal cell.
A wide variety of labels and conjugation techniques are known by those skilled in the art and can be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting related sequences include oligolabeling, nick translation, and end-labeling or PCR amplification using a labeled nucleotide. Suitable reporter molecules or labels include those radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles and the like. The term may also be used in reference to proteins. For example, a variety of protocols which employ polyclonal or monoclonal antibodies specific for the β-peptide protein product are known in the art (See, the Examples). These antibodies can be used as markers for the expression of proteins. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS).
The term "gene" refers to a DNA sequence that comprises coding sequences necessary for the production of a polypeptide or precursor. In some instances, a gene can also include control sequences. The polypeptide can be encoded by a full length coding sequence or by any portion of the coding sequence so long as the desired enzymatic activity is retained.
The term "gene of interest" refers to any gene, the manipulation of which may be deemed desirable for any reason, by one of ordinary skill in the art.
The term "wild-type" refers to a gene or gene product which has the characteristics of that gene or gene product when isolated from a naturally occurring source. A wild-type gene is that which is most frequently observed in a population and is thus arbitrarily designed the "normal" or "wild-type" form of the gene. In contrast, the term "modified" or "mutant" refers to a gene or gene product which displays modifications in sequence and or functional properties (i.e., altered characteristics) when compared to the wild-type gene or gene product. It is noted that naturally-occurring mutants can be isolated; these are
identified by the fact that they have altered characteristics when compared to the wild-type gene or gene product.
The terms "targeting vector" or "targeting construct" refer to oligonucleotide sequences comprising a gene of interest flanked on either side by regulatory sequences. Preferably, the targeting vector is capable of homologous recombination such that the gene of interest is integrated by recombination.
As used herein, the terms "vector" and "vehicle" are used interchangeably in reference to nucleic acid molecules that transfer DNA segment(s) from one cell to another. The terms "expression vector" or "expression cassette" as used herein, refers to a recombinant DNA molecule containing a desired coding sequence and appropriate nucleic acid sequences necessary for the expression of the operably linked coding sequence in a particular host organism. Nucleic acid sequences necessary for expression in prokaryotes usually include a promoter, an operator (optional), and a ribosome binding site, often along with other sequences. Eukaryotic cells are known to utilize promoters, enhancers, and termination and polyadenylation signals.
The terms "in operable combination," "in operable order," and "operably linked" as used herein, refer to the linkage of nucleic acid sequences in such a manner that a nucleic acid molecule capable of directing the transcription of a given gene and/or the synthesis of a desired protein molecule is produced. The term also refers to the linkage of amino acid sequences in such a manner so that a functional protein is produced.
The term "tissue-type specific" as it applies to a promoter, refers to a promoter that is capable of selectively directing expression of a gene in a specific tissue. Similarly, the use of a tissue-specific promoter in the method of the present invention does not require absolute specificity. In general, the requisite specificity is found where a plurality (or, more preferably, a majority) of cells in one tissue type express a gene of interest, while virtually all (e.g., greater than 80%, and preferably greater than 90%, and more preferably greater than 95%), of the cells in other tissue types do not. In one embodiment of the present invention, the strong muscle promoter unc54 was used (See, Example 1).
As used herein the term "portion" when in reference to a gene refers to fragments of that gene. The fragments may range in size from a few nucleotides to the entire gene
sequence minus one nucleotide. Thus, "an oligonucleotide comprising at least a portion of a gene" may comprise fragments of the gene or the entire gene.
As used herein, the term "substantially purified" refers to molecules, either nucleic or amino acid sequences, that are removed from their natural environment, isolated or separated, and are at least 60% free, preferably 75% free, and most preferably 90% free from other components with which they are naturally associated. An "isolated polynucleotide" is therefore a substantially purified polynucleotide.
As used herein, the term "polymerase chain reaction" ("PCR") refers to the method of K.B. Mullis disclosed in U.S. Patent Nos. 4,683,195, 4,683,202 and 4,965,188, all of which are hereby incorporated by reference, which describe a method for increasing the concentration of a segment of a target sequence in a mixture of genomic DNA without cloning or purification. This process for amplifying the target sequence consists of introducing a large excess of two oligonucleotide primers to the DNA mixture containing the desired target sequence, followed by a precise sequence of thermal cycling in the presence of a DNA polymerase. The two primers are complementary to their respective strands of the double stranded target sequence. To effect amplification, the mixture is denatured and the primers then annealed to their complementary sequences within the target molecule. Following annealing, the primers are extended with a polymerase so as to form a new pair of complementary strands. The steps of denaturation, primer annealing and polymerase extension can be repeated many times (i.e. , denaturation, annealing and extension constitute one "cycle"; there can be numerous "cycles") to obtain a high concentration of an amplified segment of the desired target sequence. The length of the amplified segment of the desired target sequence is determined by the relative positions of the primers with respect to each other, and therefore, this length is a controllable parameter. By virtue of the repeating aspect of the process, the method is referred to as the
"polymerase chain reaction" (hereinafter "PCR"). Because the desired amplified segments of the target sequence become the predominant sequences (in terms of concentration) in the mixture, they are said to be "PCR amplified."
With PCR, it is possible to amplify a single copy of a specific target sequence in genomic DNA to a level detectable by several different methodologies (e.g., hybridization
with a labeled probe; incorporation of biotinylated primers followed by avidin-enzyme conjugate detection; and/or incorporation of 32P-labeled deoxynucleotide triphosphates, such as dCTP or dATP, into the amplified segment). In addition to genomic DNA, any oligonucleotide sequence can be amplified with the appropriate set of primer molecules. In particular, the amplified segments created by the PCR process itself are, themselves, efficient templates for subsequent PCR amplifications. Amplified target sequences may be used to obtain segments of DNA (e.g., genes) for the construction of targeting vectors, transgenes, etc.
As used herein, the terms "PCR product" and "amplification product" refer to the resultant mixture of compounds after two or more cycles of the PCR steps of denaturation, annealing and extension are complete. These terms encompass the case where there has been amplification of one or more segments of one or more target sequences.
The term "Central Nervous System" refers to the "spinal cord" and the "brain." The spinal cord comprises white areas and grey areas. The grey area contains nerve cell bodies, whereas the white area is essentially comprised of myelinated nerves. The brain, which is also known as the encephalon, is that portion of the cerebrospinal axis which is contained in the cavity of the cranium. The brain comprises the two cerebral hemispheres, the inter- brain, the mid-brain, the pons Varolli and cerebellum, and the medulla oblongata. The two hemispheres together with the parts derived from the thalamencephalon form the forebrain. The two cerebral hemispheres are separated by the longitudinal fissure and also comprise the bylvian fissure, the fissure of Rolando, and the parieto-occipital fissure. The lobes on the external surface of the brain comprise the frontal lobe, the parietal lobe, the occipital lobe, and the temporal lobe. Placed along the middle line of the brain are, among others, the rostrum and peduncles of corpus callosum, lamina cinera, optic commissure and the pituitary body. On each side of the middle line lies the frontal lobe, olfactory lobe and the hemisphere of cerebellum.
The terms "neuron," "neural cell," and "nerve cell" are used interchangeably to refer to a cell which is located in the nervous system. Nerve cells are composed of the nerve cell body (perikaryon), one or more dendrites, and an axon. Neurons can be classified according to the number of processes originating from the cell body. Thus,
unipolar neurons have a single process, bipolar neurons have one axon and one dendrite, while multipolar neurons (which are the most common) comprise more than two processes. The term "neuron" comprises cholinergic neurons and sensory neurons. As used herein, the term "cholinergic neuron" means a neuron in the Central Nervous System (CNS) and in the Peripheral Nervous System (PNS) whose neurotransmitter is acetylcholine. As used herein, the term "sensory neuron" includes a neuron which is responsive to environmental cues (e.g., temperature and movement) from, for example, the skin, muscle and joints of a mammal.
The term "nerve" refers to two or more neurons arranged in linear sequence such that the axon of one neuron establishes a structural and functional link with the dendrite of a second neuron to form a "synapse."
The term "compound" refers to any chemical entity, pharmaceutical, drug, and the like that can be used to treat or prevent a disease, illness, sickness, or disorder of bodily function. Compounds comprise both known and potential therapeutic compounds. A compound can be determined to be therapeutic by testing using the testing methods of the present invention (i.e., a "test compound"). A "known therapeutic compound" refers to a therapeutic compound that has been shown (e.g., through animal trials or prior experience with administration to humans) to be effective in such treatment or prevention. In other words, a known therapeutic compound is not limited to a compound efficacious in the treatment or prevention of neural related disorders.
A compound is said to be "in a form suitable for administration such that the compound is bioavailable in the blood of the animal" when the compound may be administered to an animal by any desired route (e.g., oral, intravenous, subcutaneous, intramuscular, etc.) and the compound or its active metabolites appears in the blood of the animal in an active form. Administration of a compound to a pregnant animal may result in delivery of bioavailable compound to the embryonic progeny of the animal.
The "wild-type β-amyloid" or "β-peptide" gene and gene product refers to the nucleotide and amino acid sequences provided in SEQ ID NOS:6 and 7, respectively. Those skilled in the art will be well aware that certain modifications of SEQ ID NOS:6 and 7 can be made which will not interfere with the production of a polypeptide having an
activity indistinguishable from that of the wild-type β-amyloid; the present invention specifically contemplates these variant forms of β-amyloid. A "variant" of the β-peptide is defined as an amino acid sequence that differs by one or more amino acids. The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties (e.g., replacement of leucine with isoleucine). More rarely, a variant may have "nonconservative" changes, e.g., replacement of a glycine with a tryptophan. Similar minor variations may also include amino acid deletions or insertions (i.e., additions), or both. Guidance in determining which and how many amino acid residues may be substituted, inserted or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, DNAStar software.
The term "an oligonucleotide sequence comprising at least a portion of a human β- amyloid gene" refers to a polynucleotide sequence (i.e., a nucleic acid sequence) containing a nucleotide sequence derived from a human β-amyloid gene. This sequence may encode a portion or all of the β-amyloid protein; alternatively, this sequence may contain non-coding regions derived from the β-amyloid gene or a combination of coding and non-coding regions. The oligonucleotide may be RNA or DNA and may be of genomic or synthetic origin.
As used herein the term "portion" when in reference to a gene refers to fragments of that gene. The fragments may range in size from 10 nucleotides to the entire gene sequence minus one nucleotide. Thus, "an oligonucleotide comprising at least a portion of a gene" may comprise fragments of the gene or the entire gene.
An animal whose genome comprises a "heterologous marker gene" is an animal whose genome contains a marker gene not naturally found in the animal's genome. In one preferred embodiment of the present invention, the heterologous marker gene is a mutant collagen gene, such as the rol-6 (su- 1006) gene. However, it is intended that other marker genes will be used with success in the present invention, including other mutant collagen genes, as well as other marker genes commonly known to those in the art.
As used herein, the term "diagnostic assay" refers to methods for the diagnosis of disease, illness, and/or pathology. It is intended that the term encompass any methods for
diagnosis, including, but not limited to assays based on immunoreactivity (e.g., radioimmunoassays, fluorescence immunoassays, enzyme immunoassays), histochemistry, dye retention or binding (e.g., fixing of dyes such as Congo Red), nucleic acid based diagnostic methods (e.g., identification of nucleic acid sequences associated with disease or pathology), etc.
EXPERIMENTAL The following examples are provided in order to demonstrate and further illustrate certain preferred embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof.
In the experimental disclosure which follows, the following abbreviations apply: eq (equivalents); M (Molar); μM (micromolar); N (Normal); mol (moles); mmol (millimoles); μmol (micromoles); nmol (nanomoles); g (grams); mg (milligrams); μg (micrograms); ng (nanograms); 1 or L (liters); ml (milliliters); μl (microliters); cm (centimeters); mm (millimeters); μm (micrometers); nm (nanometers); °C (degrees
Centigrade); U (units), mU (milliunits); min. (minutes); sec. (seconds); % (percent); kb (kilobase); bp (base pair); PCR (polymerase chain reaction); β-(l-42) amino acids 1-42 of β-amyloid peptide; Tris (tris(hydroxymethyl)-aminomethane); BSA (bovine serum albumin); Fisher (Fisher Scientific, Pittsburgh, PA); Sigma (Sigma Chemical Co., St. Louis, MO.); Promega (Promega, Corp., Madison, WI); Perkin-Elmer (Perkin-
Elmer/ Applied Biosystems, Foster City, CA); Senetek (Senetek, PLC, Maryland Heights, MO); Boehringer Mannheim (Boehringer Mannheim, Corp., Indianapolis, IN); Stratagene (Stratagene, Inc., La Jolla, CA); and NEB (New England Biolabs, Beverly, MA). Unless otherwise indicated, the restriction enzymes used in these Examples were obtained from NEB. C. elegans is available from the Caenorhabditis Genetics Center, at the University of Minnesota, St. Paul, MN.
EXAMPLE 1 Assembly of the β-(l-42) Minigene
In this Example, the β-(l-42) minigene used in subsequent experiments (See, Example 3) to produce transgenic C. elegans engineered to express amyloidic human proteins was constructed. As described below, these animals contained constructs in which the muscle-specific unc-54 promoter/enhancer of C. elegans drove the expression of the appropriate coding regions derived from human β-amyloid cDNA clones, as described by CD. Link, "Expression of human β-amyloid peptide in transgenic Caenorhabditis elegans, " Proc. Natl. Acad. Sci., 92:9368-9372 [1995]).
First, a minigene encoding the 42 amino acid β-amyloid peptide derived from human amyloid precursor protein cDNA was assembled. The artificial signal peptide coding sequence of vector pPD52.81 was amplified under standard conditions, using primers "SP-up" (5*-CGGGATTGGCCAAAGGACCC-3')(SEQ ID NO:l), and "SP-down" (5'-CCCGGTACCTGCTGGTGCCAGCAAGAT-3')(SEQ ID NO: 2), cleaved with Nhel and Kpnl restriction enzymes, and inserted between the unique Nhel and Kpnl sites of vector pPD49.26, to produce the construct "pCL2." This process resulted in a re- engineering of the signal peptide, such that the signal peptide cleavage site, as predicted by the consensus of von Heijne (G. von Heijne, Nucl. Acids Res., 14:4683-4690 [1986]), occurred immediately after the Gly-Thr dipeptide encoded by the Kpnl site.
A 146-bp fragment encoding amino acids 1-42 of β-amyloid, and which contained an artificial stop codon, was amplified using standard methods, from human β-amyloid precursor protein cDNA clone p4T4B (P. Ponte et al, Nature 331 :525-527 [1988]), by using primers "β-l-42-up" (5'-GGGGGTACCGATGCAGAATTCCGACATGA-3') (SEQ ID NO:3), and "β-1-42 down" (5*-CCCGAGCTCACGCTATGACAACACCGCCAA- 3')(SEQ ID NO:4). The amplification product was cleaved with Kpnl and Sad, and inserted between the unique Kpnl and Sac I sites of pCL2, to generate "pCL3." The signal peptide/β-(l-42) minigene fragment was removed from this plasmid by digestion with Nhel and Sacl, and inserted between the unique Nhel and Sad sites of pPD30.38, to produce "pCL12." The sequence of the β-(l-42) minigene was confirmed by dideoxy DNA sequencing of the coding strand only, by techniques known in the art. The sequence of pCL12 (SEQ ID NO:5), is shown in Figure 2. A graphic map of pCL12 is provided at Figure 3. Figure 4 shows the DNA and amino acid sequences (SEQ ID NOS:
6 and 7, respectively) of pCL12 from nucleotide 1071 through 1253 (i.e., the β(l-42) nucleic acid and amino acid sequences) present in the construct.
EXAMPLE 2 Construction of the hsp/GFP Reporter
In this Example, the expression vector ("pCL25") containing the hsp/GFP reporter which drives the expression of the GFP-TT gene was constructed. This vector was used in subsequent experiments (See, Example 3) to produce transgenic C. elegans was constructed. GFP-TT is a modified form of GFP that contains Ser65Thr and Ilel67Thr (the numbering is relative to the sequence of the wild-type GFP). The substitutions present in GFP-TT produce a protein which results in the production of a much brighter fluorescence than the wild-type GFP. pCL25 was constructed as described below. A 431 bp Hindlll-BamYll fragment containing the hspl6-2 promoter was excised from the plasmid "pPD49.78," by digestion with BamUl and HmdIII. This 431 bp Hindlϊl-BamHl fragment was inserted between the HmdIII (nucleotide #1) and BamΑl (nucleotide #31) sites of the GFP-TT gene in the plasmid "pGFP-TT," (available from Yishi Jin, at the University of California, Santa
Cruz), using T4 ligase (Promega). The pGFP-TT plasmid contains the coding regions for GFP-TT inserted into a Tu61 backbone. The DNA sequence of pGFP-TT (SEQ ID NO: 8) is shown in Figure 5. A schematic map of pGFP-TT is shown in Figure 6, in which unique restriction sites are shown. The pGFP-TT plasmid was digested with HmdIII and BamΑl, and the 431 bp fragment containing the hspl6-2 promoter was inserted, in order to generate the stress-inducible expression vector "pCL25." The DNA sequence of pCL25 (SEQ ID NO:9) and restriction map are shown in Figure 7. Figure 8 provides a schematic map of pCL25 in which unique restriction sites are shown.
EXAMPLE 3 Construction of Transgenic Animals
In this Example, the transgenic parent animals were produced, with one line expressing the β(l-42) minigene (designated as "CL2005") and the other line expressing the hsp/GFP reporter (designated as "CL2070"). For both lines, the transgenes were introduced into C. elegans by gonad microinjection as known in the art and described by Mello et al. (Mello et EMBO J., 10:3959-3970 [1991]). Marker plasmid pRF4 containing the gene (ro/-6"[sul006]) (SEQ ID NO:9)(pRF4 carries a 4 kb EcoRI fragment of C. elegans genomic DNA containing the r /-6[sul006] collagen gene in the Bluescribe vector
[Stratagene]; See, Mello et al, supra; and Kramer et al, Mol. Cell. Biol., 10:2081-2090 [1990]) was coinjected with the constructs, at approximately 100 ng/μl for each plasmid, into morphologically wild-type animals, and Roller transgenic progeny were recovered. The (rol-6[sul006J) gene (SEQ ID NO:9), contained within the pRF4 plasmid is a mutated C. elegans collagen gene, the expression of which produces the dominant, distinctive
"Roller" phenotype. Figures 9 and 10 show the DNA and amino acid sequences of the rol- 6 gene used in this Example, respectively.
Transmitting lines were established and maintained by selection for the Roller marker phenotype. Transgenic animals produced in this manner maintain the injected DNA as an extrachromosomal, multicopy array of variable mitotic and meiotic stability.
Strains containing chromosomally integrated transgenes were recovered by irradiation of lines containing extrachromosomal transgenic arrays with 7000 rad (1 rad = 0.01 Gy) of gamma rays from a Cesium-66 source. Progeny of irradiated animals were then screen for 100% transmittance of the marker transgene. The transgenes in both the CL2005 and CL2070 lines were chromosomally integrated, and were 100% stable.
Transgenic (i.e., as indicated by the Roller phenotype) animals produce both transgenic (i.e., Roller) and non-transgenic (i.e., non-Roller) progeny. These non- transgenic progeny were found to serve as good internal controls for phenotypic and immunohistochemical comparisons. The expression of GFP in the dual transgenic animals can be detected in less than 24 hours after the upshift of animals from 16 to 25.5°C, at all
stages of development, from late embryonic to adult. Expression of GFP resulted in the production of green fluorescence in muscle cells; intense tissue-specific expression of GFP was observed. The fluorescence can be observed using compound or dissecting epifluoroescence microscopy (i.e., with standard fluorescein excitation and emission filters). It is also contemplated that the fluorescence is observable by use of fluorimeters and cell sorters.
EXAMPLE 4 Immunohistochemistry of Transgenic Animals
In this Example, immunohistochemistry was used to confirm the transmittance of the chimeric constructs in large populations of putative integrated lines.
As described by Link (Link, 1995, supra), whole mount specimens were prepared by fixing animals in 4% paraformaldehyde and permeabilizing them with 2- mercaptoethanol collagenase as known in the art and described by Link et al. (Link et al,
Genetics 131 :867-881 [1992]). Three antibodies were used (polyclonal rabbit anti-β peptide antibody, Boehringer Mannheim; mouse monoclonal antibody Ab 4G8, available from Senetek; and monoclonal 4.1, a gift from B. Cordell at Scios Nova). The monoclonal 4.1 recognizes residues 8-15 of β-peptide. As was observed by Link (Link, 1995, supra) animals transgenic for the unc-
5 /β(l-42) minigene construct contained muscle-specific deposits of anti-β peptide immunoreactivity. Non anti-β-immunoreactivity was observed in control animals (i.e,, non-transgenic, wild-type C. elegans tested concurrently). Although C. elegans is reported to contain a homolog of the β-amyloid precursor protein gene (See, Daigle and Li, Proc. Natl. Acad. Sci., 90:2045-2049 [1993]), this sequence does not contain an apparent β- peptide domain. Thus, it would not be expected, nor did it show, cross-reactivity with the anti-β antibody used in these experiments. For dually transgenic animals, immunoreactive deposits accumulated in the body wall of the animals.
Next, to determine whether the immunoreactive deposits observed in the unc-54/ - (1-42) strains displayed the tinctural properties of classic insoluble β-amyloid, transgenic
strains were fixed and stained with thioflavin S, a fluorescent amyloid-specific dye, as known in the art, and described by Guntern and Bouras (R. Guntern and C. Bouras, Experientia 48:-10 [1992]). Thioflavin S-reactive deposits were found in all strains containing the unc-54l -(l-42) minigene constructs, but not in control wild-type animals. Whole mounts of fixed dual transgenic animals stained with coumarin-phallacidin
(a muscle-specific probe) and anti-β peptide antibody. Muscle-specific β peptide deposits were observed, and showed a qualitative correlation with the level of GFP expression in these muscle cells (i.e., cells that contained more β-peptide deposits were more green than cells with less β-peptide deposits). In addition, Congo Red and Chrysamine G, two dyes known to interact with β- amyloid and have been reported to interfere with its aggregation are tested on the dually transgenic animals. Anti-oxidants (e.g., vitamin E and ascorbate) are also tested. In these experiments, interference with aggregation of β-peptide, or interaction with β-amyloid are observed.
All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.
Claims
1. A transparent animal comprising:
(a) a toxic transgene;
(b) an inducible promotor operably linked to a reporter gene, wherein the toxic transgene induces the promotor and wherein the expression of the reporter gene is detectable in vivo.
2. The transparent animal of claim 1, wherein the inducible promoter operably linked to the reporter gene is stably integrated into the genome of the animal.
3. The transparent animal of claim 2, wherein the inducible promotor is induced by disruption of cellular function.
4. The transparent animal of claim 2, wherein the inducible promoter is a heat shock promoter.
5. The transparent animal of claim 2, wherein the toxic transgene is ╬▓-peptide.
6. The transparent animal of claim 2, wherein said transparent animal is selected from the class Nematoda.
7. The transparent animal of Claim 6, wherein said transparent animal is
Caenorhabditis elegans.
8. The transparent animal of Claim 2, wherein said genome comprises SEQ ID NO:5 and SEQ ID NO:8.
9. The transparent animal of Claim 2, wherein said reporter gene is green fluorescence protein (GFP).
10. The transparent animal of claim 1, further comprising a heterologous gene marker.
11. A method for producing a dually transgenic non-human animal comprising a) providing: i) a first and second non-human animal; and ii) a first toxic transgene; and iii) a second transgene, comprising a reporter; b) introducing said first toxic transgene into the genome of said first non- human animal to produce a first transgenic animal, and introducing said second transgene into the genome of said second non-human animal to produce a second transgenic animal; and c) mating said first transgenic animal with said second transgenic animal to produce a dually transgenic animal, wherein said toxic transgene and said reporter are expressed.
12. A dually transgenic non-human animal produced according to the method of claim 11 , wherein the toxic transgene is ╬▓-peptide.
13. A dually transgenic non-human animal produced according to the method of claim 11 , wherein said non-human animal is transparent.
14. The dually transgenic non-human animal of claim 13, wherein said non- human animal is a nematode.
15. The dually transgenic non-human animal of claim 14, wherein said nematode is Caenorhabditis elegans
16. The method of claim 11, wherein said reporter is green fluorescent protein.
17. The dually transgenic non-human animal produced according to the method of claim 11, wherein said first transgene comprises pCL25.
18. The dually transgenic non-human animal produced according to the method of claim 11, wherein said second transgene comprises pCL12.
19. The dually transgenic non-human animal produced according to the method of claim 11, further comprising a heterologous marker gene.
20. A method for testing compounds for toxicity, comprising: a) providing: i) a dually transgenic non-human animal expressing a toxic transgene and reporter gene operably linked to a promoter inducible by the toxic transgene; ii) a composition comprising a test compound in a form suitable for administration such that said compound is bioavailable in the cells of said non- human animal; and b) administering said test compound to said non-human animal.
21. The method according to claim 20, wherein the toxic transgene is ╬▓-peptide and the reporter gene is GFP.
22. The method of Claim 21 , further comprising c) measuring a reduction in the fluorescence of said non-human animal and thereby identifying a compound as therapeutic.
23. The method of Claim 20, wherein said compounds inactivate said ╬▓-peptide expressed by said dually transgenic animal.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77864597A | 1997-01-03 | 1997-01-03 | |
US8022297P | 1997-01-03 | 1997-01-03 | |
US80222P | 1997-01-03 | ||
US778645 | 1997-01-03 | ||
PCT/US1997/023819 WO1998028971A2 (en) | 1997-01-03 | 1997-12-31 | Transgenic animals for in vivo visualization of beta-amyloid toxicity |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0948612A2 true EP0948612A2 (en) | 1999-10-13 |
Family
ID=26763238
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP97952623A Withdrawn EP0948612A2 (en) | 1997-01-03 | 1997-12-31 | Beta-amyloid toxicity |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0948612A2 (en) |
AU (1) | AU5619298A (en) |
WO (1) | WO1998028971A2 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1294450B1 (en) * | 1997-08-28 | 1999-03-25 | Consiglio Nazionale Ricerche | TRANSGENIC ANIMALS FOR THE STUDY OF PHYSICAL OR BIOLOGICAL CHEMICAL TOXIC AGENTS |
AU6291899A (en) * | 1998-10-09 | 2000-05-01 | Regents Of The University Of California, The | Viable prp (prion protein) transgenic animals and methods of use |
DE19849073A1 (en) * | 1998-10-24 | 2000-04-27 | Aventis Pharma Gmbh | Transgene encoding amyloid precursor protein or its fragment, used to produce transgenic nematodes used, e.g. to screen for agents for treating Alzheimer's disease |
US7449615B2 (en) | 1998-12-17 | 2008-11-11 | Xenogen Corporation | Non-invasive evaluation of physiological response in a transgenic mouse |
GB9906018D0 (en) * | 1999-03-16 | 1999-05-12 | Devgen Nv | Expression of DNA or proteins in C.elegans |
WO2001018225A1 (en) * | 1999-09-03 | 2001-03-15 | Xenogen Corporation | Targeting constructs and transgenic animals produced therewith |
US6867348B1 (en) | 1999-12-16 | 2005-03-15 | Xenogen Corporation | Methods and compositions for screening for angiogenesis modulating compounds |
IT1311335B1 (en) | 1999-12-21 | 2002-03-12 | Otc Optical Technologies Ct S | PROCEDURE AND DEVICE FOR MAKING FIBER OPTIC LICENSES. |
JP3354918B2 (en) * | 2000-06-08 | 2002-12-09 | 佑子 若松 | Transparent medaka |
AU2002365538A1 (en) * | 2001-11-27 | 2003-06-10 | Nexyte Ab | Production of eukaryotic proteins and nucleic acid molecules in c. elegans |
FR2840320B1 (en) | 2002-05-30 | 2007-07-20 | Centre Nat Rech Scient | XENOPE TRANSGENIC EMBRYOS AND USES THEREOF FOR THE DETECTION OF ENDOCRINE DISRUPTORS AND METHODS THEREOF |
GB0517977D0 (en) * | 2005-09-02 | 2005-10-12 | Birkeland Innovasjon As | Transgenic animal model for identifying modulators of protein kinase |
DE102007035238A1 (en) * | 2007-07-27 | 2009-01-29 | Christian-Albrechts-Universität Zu Kiel | Biological effect monitoring by transgenic Hydra |
WO2011017319A1 (en) | 2009-08-03 | 2011-02-10 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods of treating disorders associated with protein polymerization |
US9072772B2 (en) | 2009-11-05 | 2015-07-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating disorders associated with protein aggregation |
US8809617B2 (en) * | 2009-11-05 | 2014-08-19 | The University of Pittsburgh—Of the Commonwealth System of Higher Education | Automated high-content live animal drug screening using C. elegans |
CN104920307B (en) * | 2015-06-19 | 2018-01-26 | 安徽省农业科学院农业工程研究所 | A kind of Caenorthaditis elegans ws123 fixing means suitable for single-particle microbeam device |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4240293A (en) * | 1992-05-08 | 1993-12-13 | Exemplar Corporation | Anti-neoplastic in vivo drug screen |
CA2088379A1 (en) * | 1993-01-29 | 1994-07-30 | University Of British Columbia | Biological systems incorporating stress-inducible genes and reporter constructs for environmental biomonitoring and toxicology |
CA2174429C (en) * | 1993-10-27 | 2011-08-30 | Lisa C. Mcconlogue | Transgenic animals harboring app allele having swedish mutation |
-
1997
- 1997-12-31 AU AU56192/98A patent/AU5619298A/en not_active Abandoned
- 1997-12-31 WO PCT/US1997/023819 patent/WO1998028971A2/en not_active Application Discontinuation
- 1997-12-31 EP EP97952623A patent/EP0948612A2/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO9828971A3 * |
Also Published As
Publication number | Publication date |
---|---|
WO1998028971A2 (en) | 1998-07-09 |
AU5619298A (en) | 1998-07-31 |
WO1998028971A3 (en) | 1998-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Edelmann et al. | Neuronal abnormalities in microtubule-associated protein 1B mutant mice. | |
AU671093B2 (en) | Transgenic animal models for alzheimer's disease | |
EP0948612A2 (en) | Beta-amyloid toxicity | |
EP1005542B1 (en) | APOLIPOPROTEIN E TRANSGENIC mice AND ASSAY METHODS | |
Götz et al. | Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy | |
US20100146645A1 (en) | Transgenic animal model for modelling pathological anxiety, a method for identifying compounds for treatment of diseases or disorders caused by pathological anxiety and a method for using wfs1 protein as a target for identifying effective compounds against pathological anxiety | |
US20080201786A1 (en) | Transgenic Zebrafish Models of Alzheimer's Disease | |
JP2001517065A (en) | Methods for identifying therapeutic agents for Alzheimer's disease using transgenic animal models | |
JP4290329B2 (en) | Transgenic animals | |
US20030233669A1 (en) | Perlecan transgenic animals and methods of identifying compounds for the treatment of amyloidoses | |
US8487087B2 (en) | Model animal in which state of disease condition is observable in real time, gene construct for achieving the same and use of the same | |
US5604131A (en) | cDNA-genomic DNA hybrid sequence encoding APP770 containing a genomic DNA insert of the KI and OX-2 regions | |
US20130133090A1 (en) | Transgenic mammalls modified in bri protein expression | |
CA2523888A1 (en) | Transgenic rat and the use thereof in the animal model for human huntingdon's disease and nuclear constructs, vectors and cells for the production thereof | |
JP5046413B2 (en) | Targeted recombinant non-human mammal with human FAD presenilin mutation and reproductive progeny | |
EP1116790A1 (en) | Murine models characterized by conditional mutation of SMN gene - use for study of spinal muscular atrophy and other neurodegenerative diseases and muscular myopathies | |
Buck et al. | Experimental models of tau aggregation | |
US7445904B2 (en) | Cysteine string protein and its role in neurodegenerative diseases | |
Wadsworth et al. | Transgenic mouse expressing APP 770 | |
Wang | The functions of FE65 proteins and their roles in dementias of the Alzheimer type | |
Cho et al. | Ha HY, Cho IH, Lee KW, Lee KW, Song JY, Kim KS et al.. The axon guidance defect of the telencephalic commissures of the JSAP1-deficient brain was partially rescued by the transgeni... | |
WO2007085706A1 (en) | Method for screening substances for treatment of neuropsychiatric diseases and materials therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19990712 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): CH DE FR GB LI |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20010703 |